Graduate Theses, Dissertations, and Problem Reports
2008

Constructing gene expression based prognostic models to predict
recurrence and lymph node metastasis in colon cancer
Ramakanth Reddy Mettu
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Mettu, Ramakanth Reddy, "Constructing gene expression based prognostic models to predict recurrence
and lymph node metastasis in colon cancer" (2008). Graduate Theses, Dissertations, and Problem
Reports. 4406.
https://researchrepository.wvu.edu/etd/4406

This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Constructing gene expression based prognostic models to predict
recurrence and lymph node metastasis in colon cancer
Ramakanth Reddy Mettu

Thesis Submitted to the
College of Engineering and Mineral Resources
at West Virginia University
in partial fulfillment of the requirements
for the degree of

Master of Science
in
Electrical Engineering

Nancy Lan Guo, Ph.D., Chair
Bojan Cukic, Ph.D.
Tim Menzies, Ph.D.
Lane Department of Computer Science and Electrical Engineering
Morgantown, West Virginia
2008

Keywords: Random forests, Feature selection, Machine learning, Classification, Colon
cancer, Recurrence, Kaplan-Meier

ABSTRACT
Constructing gene expression based prognostic models to predict recurrence and lymph node
metastasis in colon cancer
Ramakanth Reddy Mettu
The main goal of this study is to identify molecular signatures to predict lymph node metastases and
recurrence in colon cancer patients. Recent advances in microarray technology facilitated building of
accurate molecular classifiers, and in depth understanding of disease mechanisms.
Lymph node metastasis cannot be accurately estimated by morphological assessment. Molecular markers
have the potential to improve prognostic accuracy. The first part of our study presents a novel technique
to identify molecular markers for predicting stage of the disease based on microarray gene expression
data. In the first step, random forests were used for variable selection and a 14-gene signature was
identified. In the second step, the genes without differential expression in lymph node negative versus
positive tumors were removed from the 14-gene signature, leading to the identification of a 9-gene
signature. The lymph node status prediction accuracy of the 9-gene signature on an independent colon
cancer dataset (n=17) was 82.3%. Area under curve (AUC) obtained from the time-dependent ROC
curves using the 9-gene signature was 0.85 and 0.86 for relapse-free survival and overall survival,
respectively. The 9-gene signature significantly stratified patients into low-risk and high-risk groups (logrank tests, p<0.05, n=73), with distinct relapse-free survival and overall survival. Based on the results, it
could be concluded that the 9-gene signature could be used to identify lymph node metastases in patients.
We further studied the 9-gene signature using correlation analysis on CGH and RNA expression datasets.
It was found that the gene ITGB1 in the 9-gene signature exhibited strong relationship of DNA copy
number and gene expression. Furthermore, genome-wide correlation analysis was done on CGH and
RNA data, and three or more consecutive genes with significant correlation of DNA copy number and
RNA expression were identified. These results might be helpful in identifying the regulators of gene
expression.
The second part of the study was focused on identifying molecular signatures for patients at high-risk for
recurrence who would benefit from adjuvant chemotherapy. The training set (n=36) consisted of patients
who remained disease-free for 5 years and patients who experienced recurrence within 5 years. The
remaining patients formed the testing set (n=37). A combinatorial scheme was developed to identify gene
signatures predicting colon cancer recurrence. In the first step, preprocessing was done to discard
undifferentiated genes and missing values were replaced with k=30 and k=20 using the k-nearest
neighbors algorithm. Variable selection using the random forests algorithm was applied to obtain gene
subsets. In the second step, InfoGain feature selection technique was used to drop lower ranked genes
from the gene subsets based on their association with disease outcome. A 3-gene and a 5-gene signature
were identified by this technique based on different missing value replacement methods. Both of the
recurrence gene signatures stratified patients into low-risk and high-risk groups (log-rank tests, p<0.05,
n=73), with distinct relapse-free survival and overall survival. A recurrence prediction model was built
using LWL classifier based on the 3-gene signature with an accuracy of 91.7% on the training set (n=36).
Another recurrence prediction model was built using the random tree classifier based on the 5-gene
signature with an accuracy of 83.3% on the training set (n=36). The prospective predictions obtained on
the testing set using these models will be verified when the follow-up information becomes available in
the future. The recurrence prediction accuracies of these gene signatures on independent colon cancer
datasets were in the range 72.4% to 88.9%. These prognostic models might be helpful to clinicians in
selecting more appropriate treatments for patients who are at high-risk of developing recurrence. When
compared over multiple datasets, the 3-gene signature had improved prediction accuracy over the 5-gene
signature. The identified lymph node and recurrence gene signatures were validated on rectal cancer data.
Time-dependent ROC and Kaplan-Meier analysis were done producing significant results. These results
support the fact that the developed prognostic models could be used to identify patients at high-risk of
developing recurrence and get an estimate of the survival times in rectal cancer patients.
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Chapter 1
Introduction
Colon cancer is the third most common cause of cancer in Europe and the United States, with ~300,000
new cases and 200,000 deaths each year. It is the second most common site (after lung) to cause cancer
death 1. The primary treatment for colon cancer is the surgical removal of a part of colon or the entire
colon. Chemotherapy after surgery can prolong the survival in patients if the cancer has spread to nearby
lymph nodes. Prognosis is the estimation of disease outcome i.e., the chance that a patient will recover or
have a recurrence (return of the cancer) 2. The most important factors that affect the colon cancer
prognosis are the histology, location, and stage of the disease (the extent to which the cancer has spread).
Doctors cannot be absolutely certain about the outcome for a particular patient based on the traditional
morphological assessment.

In the recent years, advances in genetic technologies such as cDNA microarrays allowed for
measuring the expression of tens of thousands of genes simultaneously. The research carried out in this
area over the past few years has demonstrated that the gene expression data could be used to solve a
variety of problems like tumor classification and prediction of treatment response. Machine learning and
statistical techniques have been successfully applied on the gene expression datasets to identify
biomarkers, predict recurrence or disease outcome, distinguish between tumor and normal tissue samples,
build prognostic predictors and predict treatment response (1). Currently, two gene expression based tests
are being used in clinical trials for breast cancer prognosis. The MammaPrint 3 test classifies tumors into

1
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low or high-risk of recurrence. The Oncotype DX 4 test determines the likelihood of recurrence. There are
no gene tests available for colon cancer prognosis at present.

Staging is an important prognostic factor in determining treatment options. Earlier stages of colon
cancer (stage I and stage II) have good chances of prognosis compared to later stages (stage III and stage
IV) 5. When a patient is diagnosed with cancer, various clinical parameters are used to assess the risk of
metastasis and death in the patient. However, despite numerous advances in this area, the ability to
accurately estimate the risk of morbidity is limited. Tumors that appear indistinguishable under the
microscope can have different outcome and different treatment response. This could be due to the
differences in the genetic profiles of the tumors. With the advent of cDNA microarray technology, it is
possible to measure the expression levels of thousands of genes simultaneously and the differences
between tumors at the molecular level can be detected. Thus molecular markers identified based on the
cDNA microarray expression data have the potential to improve prognostic accuracy significantly. The
disease prognosis can be assessed preoperatively through a tissue obtained from a colonoscopic biopsy
specimen or post operatively from a resected tumor.

The first part of our study aims at building prognostic models based on the microarray gene
expression data to predict lymph node metastasis (stage). The colon cancer microarray data used in this
study contained 73 tumor samples of which 33 samples were stage II tumors and 40 samples were stage
III tumors (2). The data was preprocessed by applying t-tests 6 on genes that had missing values in more
than 5 samples. Genes passing the t-tests along with all genes having less than 5 missing values, a total of
10,220 genes, were included for further analysis. This data was randomly split in 2:1 ratio as training and
testing sets. The training set contained 10,220 genes and 50 samples. A 9-gene lymph node status
signature was identified by a novel technique from the training set. In this technique, firstly, variable
selection using random forests (3) was done and a 14-gene signature was identified. In the next step, z4
5
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tests 7 were applied on the 14-gene signature to discard the genes without differential expression in lymph
node negative versus positive tumor samples. This resulted in a 9-gene signature. The performance of the
9-gene signature was evaluated by cross validation on independent colon cancer data sets. A number of
machine learning algorithms were applied on validation datasets, but none of the algorithms gave
consistent results on all the validation datasets. So, classifiers with highest prediction accuracy on each
dataset were chosen. J48, Naïve Bayes, Decision stump and Threshold selector were the classifiers used
for validation of independent datasets. The 9-gene signature was used to predict lymph node status on
Koinuma et al data (n=17), recurrence on Barrier et al data (PMID 16091735) (n=12), Barrier et al data
(PMID 16966692) (n=50), Barrier et al data (PMID 17043639) (n=24), and drug response on NCI-60 8
data (n=34). Further time-dependent ROC analysis was done to get an estimate of the discriminatory
power of the identified biomarker. Kaplan-Meier analysis generated significant patient stratification into
subgroups (p<0.05, n=73, log-rank tests) with distinct relapse-free survival and overall survival,
respectively. Correlation analysis was done on CGH and RNA data to identify cDNA copy numbers
correlated with gene expression data. The locations of these genes might be important in identifying the
regulators of the gene expression (4).
Recurrence is the reappearance of a tumor or the return of symptoms after treating for cancer.
Adjuvant chemotherapy is the main treatment given to Duke’s stage C patients (node-positive disease). In
Duke’s stage B patients (node negative disease) no adjuvant chemotherapy is used after surgery, although
25% to 40% of patients usually develop recurrence (5). It is not clear whether adjuvant chemotherapy
should be given to Duke’s stage B patients as not all the patients would benefit from it. Partitioning
patients into low-risk and high-risk groups would allow in “more aggressive” and accurate treatment
strategies for the patients at high-risk of recurrence, and spare the patients in the low-risk group from the
“aggressive treatment” through which they are unlikely to be benefited. The TNM (tumor-nodemetastasis) staging system is the main tool for identifying prognostic differences (6), but this system is
7
8
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not sufficient for predicting recurrence in Duke’s stage B patients (7). Thus, there are limitations for
predicting recurrence by using traditional methods. So there is a need to identify patients at high-risk of
recurrence who would develop relapse in the Duke’s B group.

The second part of our study specifically aims at identifying patients at high-risk of recurrence by
building prognostic models for stage II (Duke’s stage B) and stage III (Duke’s stage C) colon cancer
patients. This is achieved by a novel combinatorial feature selection scheme. The missing values in the
gene expression data were replaced by k-nearest neighbors algorithm with k=30 and k=20, separately. In
the first step, variable selection using random forests is done on the training set which comprised of 36
patients. This step obtained two recurrence gene signatures based on different missing value replacement
methods. In the second step, InfoGain feature selection technique (12) was applied to further reduce the
dimensionality, and this led to the identification of the 3-gene signature and the 5-gene signature on
datasets generated with different missing value replacements. The performances of both gene signatures
were evaluated by cross validation on independent colon cancer data sets. A number of machine learning
algorithms have been tested for the validation of these signatures, but no particular scheme gave
consistent results on all the datasets. So, classifiers with highest prediction accuracy on each dataset were
chosen. LWL and Random Tree were the classifiers chosen to build prediction models using 3-gene and
5-gene signatures, respectively. KStar, AD Tree, IB1 and Threshold selector were the classifiers used for
validation of independent datasets. The 3-gene and 5-gene recurrence signatures were used to predict
lymph node status on Koinuma et al data (n=17), recurrence on Barrier et al data (PMID 16091735)
(n=12), Barrier et al data (PMID 16966692) (n=50), Barrier et al data (PMID 17043639) (n=24), and
drug response on NCI-60 9 data (n=34) independently. Further, time-dependent ROC analysis was done to
get an estimate of the discriminatory powers of the identified gene signatures. Prediction models were
built with the 3-gene signature and the 5-gene signature using classifiers in Weka 10 to predict recurrence
in patients from the testing set. Kaplan-Meier analysis using the 3-gene signature generated significant
9

http://discover.nci.nih.gov/cellminer/loadDownload.do

10

http://www.cs.waikato.ac.nz/ml/weka/

4

patient stratification into low-risk and high-risk groups (p < 0.05, n=73, log-rank tests,) with distinct
relapse-free survival and overall survival, respectively. Kaplan-Meier analysis using the 5-gene signature
generated significant patient stratification into low-risk and high-risk groups (p < 0.05, n=73, log-rank
tests) with distinct relapse-free survival and overall survival, respectively. When the 3-gene and 5-gene
signatures were compared over multiple datasets the 3-gene signature had improved prediction accuracy.
But the difference in the prediction accuracies was not statistically significant. From these results it can be
concluded that it is possible to build prognostic models based on the microarray gene expression data to
identify patients at high-risk of recurrence. The identified gene signatures were validated on rectal cancer
data and they generated significant patient stratification into low-risk and high-risk groups.

This thesis is organized as follows. Chapter 2 discusses the background of our study. Chapter 3
describes the experimental details of the identification and validation of the 9-gene signature and the
validation results. Chapter 4 describes the experimental details of identification and validation of the 3gene and 5-gene recurrence signatures. Chapter 5 discusses the validation results of all the gene signatures
on rectal cancer data, and Chapter 6 concludes this study.
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Chapter 2
Background
2.1 Introduction
Gene signatures can be used to aid clinical decision-making in personalized therapy. They can also be
used to stratify patients who would experience recurrence and who would not. The goal of our study is to
identify a small subset of genes that could potentially be used to predict the likelihood of lymph node
metastases (stage) and recurrence in patients with colon cancer. Prognostic models can be built based on
these gene signatures to identify patients at high-risk of recurrence. These gene signatures have the
potential for improving diagnostic classification, treatment selection, and prognostic assessment.

The advent of high-throughput technologies such as DNA microarrays is currently
revolutionizing biology and medicine. Machine learning techniques are playing a pivotal role in analyzing
the generated microarray data. Machine learning algorithms are very useful in cancer research and several
machine learning algorithms have already been successfully applied on microarray gene expression data
to classify tumors, predict disease outcome and treatment response (8). Unsupervised machine learning
approaches such as, self-organizing maps (SOM) were used to organize genes into biologically relevant
clusters in leukemia (11), and hierarchical clustering was used to classify colon cancer tissues into
cancerous and non-cancerous based on the gene expression (9). Supervised machine learning techniques
such as Support vector machines (SVMs) were used for multi-class cancer diagnosis (10). Nearest
shrunken centroids were used for diagnosing cancer (38). Decision trees and feed-forward neural
networks were used for lung cancer classification (39).

The remainder of this chapter is organized as follows. Section 2.2 describes the feature selection
techniques utilized in this study. Section 2.3 describes the classification algorithms used in this study.
Section 2.4 explains the survival analysis techniques. Section 2.5 describes the correlation coefficient
6

analysis. Section 2.6 presents the related work performed in previous studies. Section 2.7 discusses the
open problems in this area, and Section 2.8 summarizes this chapter.

2.2 Feature selection techniques
Two of the most important problems in microarray data analysis relate to the dimensionality of the data
and noise. In many bioinformatics problems, the number of features is significantly larger than the
number of samples (high feature to sample ratio). Moreover, not all the features are necessary for
classification purposes. Inclusion of all the features would contribute noise and introduce an error.
Feature selection is the process of systematically reducing the dimensionality of a dataset to an
optimal subset of attributes for classification purposes. The main idea of feature selection is to choose a
subset of input variables. Feature selection can significantly improve the comprehensibility of the
resulting classifier models by eliminating features with little or no predictive information. Several
commonly used feature selection techniques like Random forests, Information gain attribute evaluator,
CfsSubset evaluator, GainRatio evaluator, and ReliefF attribute evaluator are described as follows.

2.2.1 Variable selection using Random forests
Random forests are an ensemble method that combines several individual classification trees. In order to
grow these ensembles, random vectors are generated that govern the growth of each tree in the ensemble.
The basic step of random forests is to form diverse tree classifiers from a single training set. Each tree is
built upon a “bootstrap sample” taken from the training set. A random subset from the whole set of
variables are used for splitting the tree nodes. The classification decision of a new case is obtained by
majority voting over all trees unless the cut-off value is user defined. In random forests, about one-third
of the cases in the bootstrap sample are not used in growing the tree. These cases are called “out-of-bag”
(OOB) cases and are used in evaluating the performance of the algorithm.
Random forest returns several measures of variable importance. The most reliable measure is the
“mean decrease in accuracy”. Mean decrease in accuracy considers the importance of an mth variable as
7

the difference between the “out-of-bag” error rate for the randomly permuted mth variable (the error rate

obtained by randomly rearranging the values of the mth variable for the out-of-bag set, for each tree,
and getting new classifications for the forest, by putting this permuted set down the tree) and the
original “out-of-bag” error rate (41). Based on the “mean decrease in accuracy” measure, backward
elimination was used to identify the gene subset with the smallest “out-of-bag” error rate. The OOB error
rate was used to choose the final set of genes, not to obtain estimates of the error rate. This procedure was
implemented using the varSelRF 11 package in R12 software.

2.2.2 Information gain attribute evaluator
Information gain (InfoGain) attribute evaluator is a supervised attribute filter for selecting attributes. This
method evaluates the attributes by measuring information gain with respect to class. Numeric attributes
are first discretized using the MDL-based discretization method 13. This method treats missing value as a
separate value or distributes the counts among other values in proportion to their frequency. It is used in
conjunction with the Ranker which ranks attributes by their individual evaluations. It is only capable of
generating attribute rankings (12). The user can specify the number of attributes to retain and the
threshold can be adjusted to discard the attributes.
The information gain of a given attribute X with respect to the class attribute Y is given by:
(Equation 1)
where H(X) is the entropy of X, H(Y) is the entropy of Y, and H(X,Y) is the joint entropy of X and Y.

2.2.3 CfsSubset evaluator
Subset evaluators take a subset of attributes and return a numeric measure that guides the search.
CfsSubset evauator assesses the predictive ability of each attribute individually and the degree of
11
12
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redundancy among them, preferring sets of attributes that are highly correlated with the class but having
low inter-correlation. Conditional entropy is used to provide a measure of the correlation between features
and class and between features. If H(X) is the entropy of a feature X and H(X|Y) the entropy of a feature X
given the occurrence of feature Y, the correlation between two features X and Y can then be calculated
using the symmetrical uncertainty as follows:

(Equation 2)

The class of an instance is considered to be a feature. The goodness of a subset is then determined as:

(Equation 3)

where k is the number of features in a subset, rci is the mean feature correlation with the class and rii is the
mean feature correlation.

2.2.4 GainRatio attribute evaluator
GainRatio attribute evaluator evaluates attributes by measuring their gain ratio with respect to the class.
If X represents the attribute and Y represents the class the GainRatio is given by the following equation:
(Equation 4)
where H(Y) is the entropy of Y, H(X) is the entropy of X, and H(Y/X) is the entropy of Y given X.
Missing value counts can be distributed across other values in proportion to their frequency or they can be
treated as separate values.

2.2.5 ReliefF attribute evaluator
ReliefF attribute evaluator evaluates the worth of an attribute by repeatedly sampling an instance and
considering the value of the given attribute for the nearest instance of the same and different class. It can
operate on both discrete and continuous class data. ReliefF generalizes the behavior of Relief to

9

classification. It finds one nearest neighbor of I1 from every class. On these neighbors Relief evaluates the
relevance of every feature f Є F accumulating it into W[f]. The nearest neighbor from the same class is a
hit H, and from a different class is a miss M(C) of class C. At the end W[f] is divided by m to get the
average evaluation in [–1, 1].

(Equation 5)

The function diff (f;I1; I2) calculates the difference between the values of the attribute A for two instances
I1 and I2. For nominal attributes it is defined as:

(Equation 6)

For numerical attributes it is defined as:

(Equation 7)

2.3 Classification algorithms
Machine learning is a subfield of Artificial Intelligence dealing with the development of algorithms that
learn from past experience. Machine learning techniques are extensively applied to microarray data,
particularly for diagnostic purposes. Especially in cancer diagnostics, microarray classification tools are
used for cancer subtype discrimination and outcome prediction. The following section describes the
machine learning algorithms that we have used in our research for predicting disease subtype and
outcome, and building prognostic models.

2.3.1 Bagging
Bagging stands for bootstrap aggregating. Given a training set, the original training data is altered by
deleting some instances and replicating others. Instances are randomly sampled with replacement from

10

the original dataset to create a new one of the same size. Instead of obtaining independent datasets from
the domain, bagging just resamples the original training data. Then, a learning scheme like a decision tree
is applied to each of these derived datasets and the classifiers generated from them vote for the class to be
predicted. All models receive equal weights and bagging produces a combined model that often performs
significantly better than the single model built on the original training data (12).

2.3.2 Naive Bayes
The classifier is named so, because it is based on Baye’s rule and assumes that the attributes are
independent “naively”. It is particularly suitable when the dimensionality of the inputs is high. Despite its
simplicity, Naive Bayes can often outperform more sophisticated classification methods. If the data is
redundant, Naive Bayes classifier works well with some attribute selection procedures that eliminate
redundant data. The Bayes rule is described as follows.
If H is the hypothesis and E is the evidence that bears on that hypothesis, then

P (H|E) = P(E|H) P(H) / P(E)
or

(Equation 8)

(Equation 9)

2.3.3 Threshold selector
Threshold selector is a Meta classifier that selects a threshold on the probability distribution output by a
classifier. The threshold is set so that a given performance measure is optimized. The performance
measure is the F-measure 14 (Equation 3). Performance can be measured either on the training data, on a
hold-out set, or using cross-validation (12).

(Equation 10)

14
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2.3.4 Locally Weighted Learning (LWL)
LWL belongs to the class of instance-based learners. It assigns weights using an instance-based method
and builds a classifier from the weighted instances. Attribute normalization is turned on by default. The
base classifier can be selected by the user. Naive Bayes is a good choice for classification problems.
Other parameters that can be adjusted are k-nearest neighbor (KNN). This method determines the number
of neighbors used to determine the width of the weighting function, and the kernel shape to use for
weighting, which can be linear, inverse, constant or Gaussian (12).

2.3.5 Multilayer Perceptron
Multilayer Perceptron is a neural network classifier. It belongs to the class of supervised neural networks.
It is one of the most important and widely used network models. The multi-layer perceptron neural
network model consists of a network of processing elements or nodes arranged in layers, usually
interconnected in a feed-forward way. Each neuron in one layer has directed connections to the neurons
of the subsequent layer. This classifier uses back propagation technique for learning. In MLPs, learning is
supervised with separate training and recall phases.
1. The network produces an output pattern for each input pattern.
2. The actual output is compared with the known output from the training set and the error is
calculated.
3. The weights are adjusted to reduce the error.
4. The steps 1-3 are repeated many times for every instance in the training set until the error is
minimized.
Once the network has been trained, the weights are then fixed. The testing set is fed into the network and
the network output is compared with the desired output.

12

2.3.6 J48
The Weka package implements its own version of C4.5 known as J48. This algorithm induces decision
trees for classification by using the greedy technique. A decision-tree model is built by analyzing the
training data and that model is used to classify testing data. If the test data is not available, J48 performs a
cross-validation using the training data.

2.3.7 IB1
The IB1 classifier is a 1-nearest neighbor instance-based classifier. It is the simplest instance-based
learning algorithm. It uses a simple distance measure to find the training instance closest to the given test
instance and assigns the same class as that of the training instance. If multiple closest instances are found,
the first one found is used. Generally the distance measure used is the Euclidean distance. An advantage
of instance-based learning over many other machine learning methods is that new examples can be added
to the training set at any time. Though instance-based learning is simple and works very well, it is often
slow (12).

2.3.8 KStar
KStar is an instance-based classifier, meaning that the class of a test instance is based upon the class of
those training instance(s) that resemble it most. The resemblance is calculated by using the distance
function. KStar uses an entropy-based distance function. This way it differs from other instance-based
classifiers. It belongs to the class of k-nearest neighbor classifiers because it classifies each instance by
looking at the nearest k data points and determining the class by the one which is the most common in the
nearest k data points (13). KStar has an option to specify the blend factor which specifies how the
distance function used to compute the k-nearest neighbors acts. If the blend factor is set to 0%, the
distance function performs like a standard nearest neighbor classifier by selecting just one instance to
classify the test instance. If the blend factor is set to 100%, the distance function takes many instances and
then classifies by the most common class.

13

2.3.9 Alternating Decision Tree (AD Tree)
Alternating decision tree is a generalized representation of both voted stumps and decision trees. It uses
boosting as a method for learning data. AD Tree supports only two-class problems. The number of
boosting iterations can be manually tuned to suit the dataset and the desired complexity/accuracy tradeoff.
More boosting iterations result in larger and potentially more accurate trees, but make the learning
process slower (12). Each of the iterations adds three nodes to the tree (one split node and two prediction
nodes) unless merging occurs. The default search method is an exhaustive search. Heuristic search
methods can be used to speed up learning but they are not guaranteed to find an optimal solution. The
instance data can be saved for visualization.

2.3.10 AdaboostM1
AdaboostM1 is a variant of Adaboost technique for multi-class problems. Adaboost stands for adaptive
boosting. Boosting is one type of meta-learning scheme that tries to build a good learning algorithm based
on a group of weak classifiers. In boosting, weighting is used to give more weight to more successful
models. It can be applied to any classification learning algorithm. By weighting the instances, the learning
algorithm can be forced to concentrate on a particular set of instances with more weight. Such instances
are important because there is a greater incentive to classify them correctly (12).

2.3.11 Decision Stump
Decision Stump is a weak learner consisting of one-level binary decision tree. It is usually used in
conjunction with a boosting algorithm. It implements regression based on the mean-squared error or
classification based on the entropy.

2.3.12 Multiboost AB
Multiboosting is an extension to the Adaboost technique for forming decision committees. It can be
viewed as a combination of Adaboost and wagging (a variant of bagging) techniques, combining the high
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bias of Adaboost technique and variance reduction property of wagging. This technique produces lower
error than Adaboost or wagging. C4.5 is used as the base learner (14).

2.3.13 JRip
JRip implements a propositional rule learner called the ripper algorithm, an acronym for repeated
incremental pruning to produce error reduction including heuristic global optimization of the rule set.
Classes are examined in increasing size and an initial set of rules for the class is generated using
incremental reduced-error pruning.

2.3.14 Random Committee
Random Committee builds an ensemble of randomized base classifiers and averages their predictions.
Each base classifier is based on the same data but uses a different random number seed. This only makes
sense if the base classifier is randomized, otherwise all classifiers would be the same (12).

2.3.15 Logistic Regression
This algorithm implements a multinomial logistic regression model with a ridge estimator. Logistic
regression is a model used for prediction of the probability of occurrence of an event by fitting data into a
logistic curve. There are some modifications in the implementation compared to the original logistic
regression which does not deal with instance weights. The algorithm is modified a little bit to handle the
instance weights (15). Ridge regression is a good method for obtaining more stable parameter estimates
for the logistic regression model.

2.4 Survival Analysis
Survival analysis is a branch of statistics dealing with the death in biological organisms and failure in
mechanical systems. Survival analysis examines and models the time it takes for events to occur. In our
context, death from diseases can be considered as an event in the survival analysis. Survival models can
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be imagined to consist of two parts: the underlying hazard function describes how hazard (risk) changes
over time and the effect parameters describe how hazard relates to other factors such as the choice of
treatment, as in a medical scenario. When applied in the area of bioinformatics, survival analysis attempts
to answer questions such as: what fraction of a population is expected to survive past a certain time? Of
those that survive, at what rate will they die? Can multiple causes of death be taken into account? How do
particular circumstances or characteristics increase or decrease the odds of survival? 15

2.4.1 Cox proportional hazards model
Proportional hazards models are a sub-class of survival models in statistics, based on the assumption that
effect parameters multiply hazard. For example, if taking drug X halves the hazard at time 0, it also
halves the hazard at time 1, or at time t for any value of t. The effect parameters estimated by any
proportional hazards model can be reported as hazard ratios. Sir David Cox observed that if the
proportional hazards assumption holds (or, is assumed to hold) then it is possible to estimate the effect
parameter(s) without any consideration of the hazard function 16. This approach to survival data is called
application of the Cox proportional hazards model. It is a broadly applicable and the most widely used
method of survival analysis for exploring the relationship between the survival of a patient and several
explanatory variables (16).

(Equation 11)
The baseline hazard function is given as α (t) = log h0(t)

The above equation represents a semi-parametric model as the baseline hazard model. It can take any
form where i represents the subscript for observation, x represents the covariates, constant α represents the
log-baseline hazard.

15
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or

(Equation 12)

Consider two observations i and i’ that differ in their x-values, with the corresponding linear predictors as
follows:

(Equation 13)

(Equation 14)

The hazard ratio for these two observations is as follows:

(Equation 15)

(Equation 16)

Given the survival times, status (alive or dead) and one or more covariates, Cox proportional hazards
model produces a baseline survival curve, covariate coefficient estimates and their standard errors, risk
ratios, 95% confidence intervals, and significance levels. A positive regression coefficient implies that the
hazard is higher and thus the prognosis is worse for higher values. Conversely, a negative regression
coefficient implies a better prognosis for patients with higher values of that variable.

2.4.2 Kaplan-Meier curves
Survival curves plot percentage of survival as a function of time. The Kaplan-Meier method is one of the
techniques used for plotting survival curves. It is used to find out the proportion of the patients living for
a certain amount of time after the treatment. The advantage of the Kaplan-Meier curve is that it takes into
account, the “censored” data. A plot of the Kaplan-Meier estimate of the survival function is a series of
horizontal steps of declining magnitude. In the Kaplan-Meier method, survival is recalculated every time
a patient dies (17).
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To calculate the fraction of patients who survived in a particular interval of time, divide the
number alive at the end of the interval by the number alive at the beginning of the interval (excluding any
censored patient in that interval from both the numerator and the denominator). This method
automatically accounts for censored patients, as both the numerator and denominator are reduced for the
interval when a patient is censored (18).
2.4.2.1 Kaplan-Meier estimator
Consider that a cohort has n individuals and t1 , t2, t3........denote the actual times of death of the n
individuals and d1, d2, d3 …… denote the number of deaths that occur at each of these times. Let n1, n2
,n3…….be the corresponding number of patients remaining in the cohort.

(Equation 17)

The above equation represents the Kaplan-Meier estimator of the survival function S(t).

2.4.2.2 Interpretation of Kaplan-Meier Curves
•

The Y- axis represents the estimated probability of survival.

•

Precision of estimates depends on the number of observations, so the estimates on the left-hand
side are more precise than the ones on the right-hand side. This is due to the less number of
deaths and censored cases.

•

But if a patient dies during the trial, then the survival curve reflects the patient's death at the
appropriate time interval with a step down.

•

The curve takes a step down every time a patient dies.

•

The small blips or vertical tick-marks on the curve indicate when (time) the patient has been
censored.

•

Probability of surviving to any point is estimated from cumulative probability of surviving in
each of the preceding time intervals (calculated as the product of preceding probabilities).
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•

There is another effect of censoring on the curve. As the patients are censored it reduces the
number of patients contributing to the curve, so each death occurring after censoring represents a
higher proportion of the remaining patients, and so every step down afterwards will be a bit larger
than it would have been.

2.4.3 Log-rank test
Log-rank test is used to compare the survival of two groups of patients. Consider a survival plot showing
two survival curves, one for low-risk group and the other for high-risk group. Looking at the curves, one
can arrive at a conclusion that the low-risk group differs from the high-risk group (or vice versa) at an
arbitrary time point, but nothing can be said about the two groups looking at the total survival time span.
So we use the log-rank test which tells us whether the two groups differ significantly or not. The log-rank
test is used to test the null hypothesis that there is no difference between the populations in the probability
of an event (e.g. death) at any time point. A value of p < 0.05 indicates that the difference between the
two groups is statistically significant. The log-rank test assumes that censoring is unrelated to the
prognosis, and the survival probabilities are the same for subjects irrespective of the times when they
were enrolled in the study. It is only a test of significance and it cannot provide an estimate of the
difference between the groups or a confidence interval (19).

2.4.4 Time-dependent ROC curves
ROC curves display sensitivity and specificity of a continuous diagnostic marker for a binary disease
variable. Time-dependent ROC curves take the disease outcome into account and vary as a function of
time. In our study the binary disease variable R(t) = 1, if the patient had recurrence prior to time t,
otherwise R(t) = 0. For a diagnostic marker M, both sensitivity and specificity are defined as a function of
time t, as follows:
Sensitivity(c,t)=P{M>c|R(t)=1}

(Equation 18)

Specificity(c,t)=P{M≤c|R(t)=0}

(Equation 19)
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A time-dependent ROC curve is a plot of 1 – specificity(c, t) versus sensitivity(c, t) for all possible values
of threshold c. Sensitivity and specificity can be used to quantify the diagnostic ability of the test.
Sensitivity is the probability that the test is positive, given that the person has the disease. Specificity is
the probability that the test is negative, given that the person does not have the disease (20). The higher
the ROC curve, the better is its capacity for discriminating diseased from non diseased subjects. ROC
curves can also be used for comparing the discriminatory capacity of different diagnostic markers. In our
study, the disease status changes with time. Some patients die as time progresses due to the disease or
recurrence. So, we use time-dependent ROC curves instead of the classical ROC curves. There are
different estimators for the ROC curves. We use the Kaplan-Meier based simple estimator in our ROC
analysis.

2.5 Correlation coefficient
Correlation coefficient 17 indicates the strength of the relationship between two random variables. The
correlation coefficient ρX,Y between two random variables X and Y with expected values μX and μY and
standard deviations σX and σY is defined as:

(Equation 20)
If we have a series of n measurements of X and Y written as xi and yi where i = 1, 2, ..., n, then the
Pearson product-moment correlation coefficient can be used to estimate the correlation of X and Y . The
Pearson correlation coefficient is given by the formula mentioned below.

(Equation 21)

Correlation analysis is frequently used in microarray data analysis to measure the association between the
variables. In our research, correlation analysis is used in validating cDNA microarray data by finding the
17
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correlation between the gene copy number and RNA expression. This might be useful in understanding
the genomic and proteomic level alterations in patients.

2.6 Related studies
Machine learning techniques and algorithms have been applied on microarray data from long time for
tumor classification, prognosis prediction, and drug response prediction. This section describes some of
the studies in the areas of tumor classification and prognosis prediction which are relevant to our research.
The study by Kwon et al (21) identified the genes involved in the carcinogenesis and progression
of colorectal cancer by analyzing the gene-expression profiles of colorectal cancer cells using cDNA
microarray. The samples and genes were classified by using a two way clustering analysis which
identified genes that were differentially expressed in the cancerous and noncancerous tissues. Genes
associated with lymph node metastasis were identified by using the k-nearest neighbors method. A 60gene predictor correctly classified 10 of 12 patients (83.3%) as having colorectal cancer with lymph node
metastasis versus those without metastasis.
The study by Koehler et al (22) created gene expression profiles from 25 colorectal carcinomas,
corresponding normal colonic mucosa, and 14 liver metastases using cDNA arrays containing 1176
cancer related genes. Hierarchical clustering clearly distinguished carcinomas from non-cancerous tissues,
separated tumors into high-stage and low-stage groups, and correlated with the histopathological
classification in 87.0% of the cases. Statistical analysis (Mann–Whitney U test) revealed 40 tumorspecific genes which allowed identification of malignant tissue samples by clustering analysis. A specific
expression signature in matching metastases was not found, but a set of 23 genes with statistically
significant expression patterns (p < 0.001) in high and low stage tumors were identified.

The study by Croner et al (23) calculated the prediction rates for lymphatic metastasis using
conventional clinicopathological parameters, gene expression data, and a combination of both. Prediction
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error, specificity, and sensitivity were analyzed using six different statistical classifiers. Analysis of
conventional parameters produced a positive prediction rate that ranged between 53% and 61%.
Microarray prediction rates were between 62.0% and 67.0% for lymphatic metastasis. It was concluded
that the prediction of lymphatic metastasis can be improved by gene expression profiling of the primary
tumor biopsy alone, or in combination with conventional parameters.
The study by Barrier et al (24) aimed at building a prognosis predictor that could be used for both
stage II and stage III colon cancer patients to identify patients at high-risk of recurrence. The k-nearest
neighbor classifier was used as a predictor. The main parameters of this classifier, the number of
informative genes and the nearest neighbors k were chosen using cross validation. For both types of
predictors (non-neoplastic mucosa and tumor based), 150 different pairs of parameters were considered
and the performance of the corresponding predictors was assessed using six-fold cross-validation. Based
on the results of cross validation, a 30-gene tumor based predictor and a 70-gene non-neoplastic mucosa
based predictor were built on the whole set of patients. As a second set of independent samples was not
available, a double cross-validation design was used, with an ‘inner level’ six-fold cross-validation for
parameter selection and an ‘outer level’ three-fold cross-validation for performance assessment of the
selected predictor. The estimated accuracy of the 30-gene tumor based predictor was 78.0% and that of
the 70-gene non-neoplastic mucosa based predictor was 83.0%.
The study by Barrier et al (25) focused on identifying a subgroup of patients at high-risk of
recurrence who were more likely to benefit from adjuvant chemotherapy based on non-neoplastic mucosa
microarray gene expression measures of 24 patients (10 with a metachronous metastasis, 14 with no
recurrence), for stage II colon cancer patients. The gene expression data of 24 patients was profiled using
the Affymetrix HGU133A Gene Chip. A 70-gene prognosis predictor was identified, by selecting the 70
most differentially expressed genes (the number of genes to include was set to 70 based on the previous
results) (24). A prognosis predictor was constructed by applying linear discriminant analysis on the 70-
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gene set with a mean prognosis prediction accuracy of 81.8%, a sensitivity of 73.0%, and a specificity of
87.1% on the validation set.

The study by Bandres et al (5) aimed at identifying patients at high-risk of recurrence within the
group of Duke’s stage B patients. Tumor gene expression profiles from patients with Duke’s B colorectal
cancer were analyzed by high density oligonucleotide microarrays. The results showed that a subset of 48
genes were differentially expressed with an associated probability P < 0.001 in the t-test 18. Another 11
genes, separating both the groups were identified using the Fisher criterion. Finally, 8 genes common in
both the subsets were selected. The 8-gene signature was associated with relapse in Duke’s stage B colon
cancer patients, and it was able to discriminate between relapsed and non-relapsed patients. Furthermore,
the differential expression of five genes (CHD2, RPS5, ZNF148, BRI3 and MGC23401) in colon cancer
progression was confirmed by real-time PCR in an independent set of patients of Duke’s B and C stages.

2.7 Open Problems
Microarray gene expression data is high dimensional, typically containing tens of thousands of features
and a small sample size. Many of the genes contain irrelevant information which is not necessary for
classification of the disease or phenotypes. Inclusion of these irrelevant genes increases the
dimensionality of the dataset, introduces noise, and increases the computation time due to the complex
search space. The data we analyzed in this study consisted of 73 observations of the expression levels of
each of the 10,220 genes. Due to the very few observations and many features, innovative feature
selection schemes need to be developed. Most of the studies described in the previous section explored
the microarray gene expression data by using a single feature selection technique. Usually, a single
feature selection technique is not enough to identify powerful gene signatures predicting the disease
outcome given the high dimensional nature of the microarray data. Hence, we developed a combinatorial
scheme to identify gene signatures. In the first step, we use random forests for variable selection. In the
18
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second step, different attribute selection schemes in Weka such as CfsSubset, GainRatio, InfoGain and
Relief were tested to reduce the feature set size by dropping some lower ranked features. It was found that
the combination of random forests and InfoGain yielded the best results. This combinatorial feature
selection scheme using random forests and InfoGain yields an optimal feature subspace which
differentiates well between the classes in our study.

2.8 Summary
This chapter described the variable selection methods using random forests, various classification
algorithms used in the study, the techniques used in survival analysis, the correlation coefficient analysis,
related studies and open problems. The following chapters describe in detail how these techniques were
applied on Ried et al colon cancer data to identify gene signatures, and results on independent colon
cancer and rectal cancer datasets.
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Chapter 3
Lymph node metastasis prediction model
3.1 Introduction
Accurately predicting the lymph node status or the stage of a cancer patient helps in selecting the optimal
treatment. Staging is an important prognostic factor in determining the treatment options. The 5-year
survival rate 19 in colon cancer patients with stage II tumors is ~78% and stage III tumors is ~64%. When
a patient has been diagnosed with cancer, various clinical parameters are used to assess the risk of
metastasis and death. In spite of the numerous advances in this area, tumor stage cannot be accurately
determined by morphological assessment. With the advent of cDNA microarray technology, it is possible
to measure the expression levels of thousands of genes simultaneously. Molecular markers identified
based on the cDNA microarray gene expression data, have the ability to detect differences between the
tumors at the molecular level (38). They offer improved prognostic accuracy when compared to the
traditional methods. Patients at high-risk of metastasis can be identified and treated aggressively, while
sparing other patients from the harmful effects of the invasive treatment. This chapter focuses on the
identification and validation of the 9-gene lymph node status signature based on the microarray gene
expression data in colon cancer patients.
Microarray gene expression data is highly correlated and many of the genes contain irrelevant
information which is not necessary for classification of the disease or phenotypes. So, t-test 20 was done on
genes with more than 5 missing values to evaluate the difference in proportions of missing values in node
positive versus negative groups. Genes passing the t-test along with all genes having less than 5 missing
values, a total of 10,220 genes were included for further analysis. We used a novel technique to identify
biomarkers predicting the cancer stage. In the first step, variable selection using random forests was done
19
20
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which identified a set of 14 genes. In the next step, the genes that did not have differential expression in
lymph node negative versus positive tumors were discarded, leading to the identification of the 9-gene
signature.
The discriminatory power of the 9-gene signature was evaluated by time-dependent ROC. The
area under curve (AUC) was 0.85 and 0.86 for relapse-free survival (RFS) and overall survival (OS),
respectively. The 9-gene signature generated significant patient stratification into low-risk and high-risk
groups with distinct (p=1e-04, n=73, log-rank tests) and (p=0.043, n=73, log-rank tests) relapse-free
survival (RFS) and overall survival (OS), respectively.
The remainder of this chapter is organized as follows. Section 3.2 introduces the data sets used
for validation in the experiments. Section 3.3 introduces our study design and experiments in detail.
Section 3.4 describes the validation results on multiple colon cancer datasets. Section 3.5 describes the
correlation analysis, and Section 3.6 summarizes this chapter.

3.2 Description of the data sets
Ried et al PMID 17210682: The colon cancer microarray data from Ried et al contained 22,464 genes
and 73 patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor
samples were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive).
The relapse-free survival (RFS), overall survival (OS), and recurrence information was available for each
of the patients in this dataset (2).
Koinuma et al PMID 16247484: The data used in this study was obtained from 10 specimens from each
group (MSI - and MSI +) subjected to gene expression profiling with microarrays. Affymetrix Gene Chip
Human Genome U133 Array Set HG-U133 A and B was used in this analysis. The clinical information
consisted of the Duke’s stage for each of the patients (27).
Duke’s Stage A

lymph node negative (class b)
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Duke’s Stage B

lymph node negative (class b)

Duke’s Stage C

lymph node positive (class a)

Duke’s Stage D

these samples were not considered for leave-one-out cross validation.

Barrier et al PMID 16091735: This colon cancer data set consisted of 18 patient samples and 22,283
genes. The recurrence status (yes/no) was the available clinical information. Nine of the 18 patients
developed a distant metastasis in the follow-up and the other nine patients remained disease-free for at
least 5 years. All the patients were operated on for colonic adenocarcinomas. Ten patients had no lymph
node metastasis (stage II) and did not receive any chemotherapy. The other eight patients had lymph node
metastasis (stage III) and received 6-month adjuvant chemotherapy with fluorouracil (FU) and
levamisole (24).
Barrier et al PMID 16966692: This colon cancer data set consisted of 50 patient samples and 22,283
genes. The recurrence status (yes/no) within 5 years was available in clinical data. Twenty-five patients
developed a distant metastasis in the follow-up and the other 25 patients remained disease-free for at least
5 years. All the fifty patients were operated on for a stage II colon adenocarcinoma and none of the
patients received any adjuvant chemotherapy (28).
Barrier et al PMID 17043639: This colon cancer data set consisted of 24 patients and 22,283 genes. The
recurrence status (yes/no) within 5 years was also given. Ten patients developed a liver metastasis after
surgery and the other 14 patients remained disease-free for at least 5 years. All the twenty-four patients
were operated on for stage II colon adenocarcinomas and none of these 24 patients received any adjuvant
chemotherapy (25).
NCI-60 data: The NCI-60 21 data contains a panel of 60 diverse human cancer cell lines used by the
Developmental Therapeutics Program of the U.S. National Cancer Institute to screen >100,000
compounds and natural products. The RNA expression data for the cell lines is available under the
21
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Affymetrix HG-U133A and HG-U133B chips. The drug activity data of 5-FU (fluorouracil) on all the 60
cell lines is available for download online 22.
Defining drug sensitivity and resistance: The drug activity profiles of 118 cancer agents including 5-FU
are available online. 5-FU is the drug frequently used in colon cancer treatment. The recorded drug
activities (log10 GI50) were available for the 60 human cancer cell lines. Specifically, for each drug, log10
(GI50) values were normalized across the 60 cell lines. Cell lines with log10 (GI50) at least 0.5 SD above
the mean were defined as resistant to the drug. Those with log10 (GI50) at least 0.5 SD below the mean
were defined as sensitive to the drug. The remaining cell lines with log10 (GI50) within 0.5 SD were
defined as intermediate in the range of drug responses (41). Specifically, 17 cell lines were sensitive, 26
cell lines were intermediate, and the other 17 cell lines were resistant to the drug Fluorouracil (5-FU).

22
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3.3 Study Design for the 9-gene signature
Colon cancer data from Ried et al (n=73)

Applying t-test on genes having > 5 missing values to determine differential gene
expression in lymph node negative versus positive patients

Selecting the genes passing t-test and all other genes
with ≤ 5 missing values

Randomly splitting data in 2:1 ratio as training
(n=50) and testing sets (n=23)

Missing value replacement using knn algorithm
on the training set (k=10)

Applying random forests using varSelRF package
in R software on the training set

14-gene signature

Removing the genes that did not have differential expression
between node positive and negative patients

9-gene signature

Validation on testing dataset and other colon cancer datasets,
plotting Time-dependent ROC, Kaplan-Meier plots

Figure 3.1 Block diagram of the study for 9-gene signature.
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3.3.1 Experimental procedure
Data Source The colon cancer microarray data from Ried et al. (2) contained 22,464 genes and 73 patient
samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples were
stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive).
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a
specific channel. Dividing one intensity by the other gives the expression ratio. We use log ratios as they
are lot easier to work with than the regular ratios. The log ratio (532/635) was considered for this analysis.
It is the log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm.
Data Preprocessing - t test We investigated whether the observed difference between the two groups
(node positive versus negative) represents a real difference in the total study population from which the
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test. The
number of missing values for each gene was found and t-test was done on genes with more than 5 missing
values to evaluate the difference in the proportions of missing values in node positive versus negative
groups. The genes passing the t-test (p < 0.05, two-sided) were included along with all genes having less
than 5 missing values for further processing. A total of 10,220 genes satisfied this condition.
Training dataset The data obtained in the above step was randomly split in 2:1 ratio as training set and
testing set. The expression data of the 10,220 genes and 50 patients constituted the training set.
Missing value replacement The training dataset contained missing values. They were replaced using the
EMV 23 package in R software with k=10. This technique estimates the missing values based on the knearest neighbors algorithm. This algorithm selects the k nearest rows that do not contain any missing
values to the one containing at least one missing value based on the Euclidian distance. Then the missing
values are replaced by the average of the neighbors.

23
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Biomarker identification VarSelRF 24 package in R was used in a series of steps on the training dataset
to find the important features. Lymph node status was used as the class variable. In the first step, a forest
with N trees was built and the features were ranked according to the importance of the variables. In the
second step, 20% of the variables that were least important were removed and a new forest was
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the
fitted random forests were examined and a set of 15 genes leading to the smallest error rate were selected.
There was a control gene in the identified 15 genes which was discarded leaving 14 genes. Table 3.1
shows the 14 genes.
Table 3.1 The 14-gene lymph node status signature.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PDCD5-programmed cell death 5
PLXNB2-plexin B2, mRNA
HIST1H3I-histone 1,H3i,m
DC50-hypothetical protein DC50
SR140-U2-associated SR140 protein
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
LAMB1-laminin,beta 1(LAMB1), mRNA
ITGB1-integrin,beta1 (fibronectin)
HIST1H2BO-histone 1, H2bo HIST1H2BO

24

ID
H200000411
H200004627
H200007687
H200000861
H200013045
H200019106
H200020644
H200016227
H200020589
H200004174
H200015474
H200006892
H200021334
H200013772

http://cran.r-project.org/web/packages/varSelRF/index.html
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3.3.2 Differentially expressed genes
Differentially expressed genes or discriminator genes are the genes with significantly different expression
in the two user defined groups or between samples obtained under different conditions in a gene
expression experiment. These gene signatures or disease associated markers are relevant to biological
processes. To find the differentially expressed genes, the mean expression values for each of the 14 genes
were calculated for lymph node negative and positive tumor groups separately. If the gene had a higher
value in node positive versus negative samples it was over expressed and vice versa. Table 3.2 shows the
over expressed and under expressed genes, and p-values for each gene obtained using the z-test 25. The
genes that did not have differential expression among lymph node negative and positive patients, namely,
PDCD5, HIST1H3I, SR140, LAMB1, and HIST1H2BO in the 14-gene signature were removed. Table 3.3
shows the remaining 9 genes.
Table 3.2 Over expressed and under expressed genes in the 14-gene signature between lymph node
positive and negative patients.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PDCD5-programmed cell death 5
PLXNB2-plexin B2, mRNA
HIST1H3I-histone 1,H3i,m
DC50-hypothetical protein DC50
SR140-U2-associated SR140 protein
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
LAMB1-laminin,beta 1(LAMB1), mRNA
ITGB1-integrin,beta1 (fibronectin)
HIST1H2BO-histone 1, H2bo HIST1H2BO

25

Category in lymph
node positive group
Under expressed
Under expressed
Under expressed
Under expressed
Under expressed
Under expressed
Over expressed
Under expressed
Over expressed
Over expressed
Over expressed
Under expressed
Over expressed
Under expressed

http://en.wikipedia.org/wiki/Z-test
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p-value

Significance

0.041134
0.044768
0.062525
0.038442
0.103315
0.003831
0.152485
0.002202
0.006503
0.008206
0.002299
0.166319
0.012588
0.053911

Yes
Yes
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No

Table 3.3 The 9-gene signature for predicting lymph node metastasis.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
DC50-hypothetical protein DC50
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200019106
H200016227
H200020589
H200004174
H200015474
H200021334

3.4 Results
3.4.1 Validation of the 9-gene signature on testing data (n=23)
The original data was split in 2:1 ratio as training and testing datasets, respectively. The testing data
consisted of 23 tumor samples. Eleven tumor samples were lymph node negative and the other 11
samples were lymph node positive. The data used for validation consisted of the expression of the 9-gene
signature in the 23 patient samples. Weka software was used for validation and lymph node status
(negative/positive) was predicted. Different classification schemes including J48, Logistic regression,
KStar, Threshold selector, and Multilayer perceptron were applied to this dataset to find the best scheme.
Table 3.4 shows the comparison between J48 and some of the classifiers used for validation on other
datasets. J48 classifier performed better than the other classifiers. It had a sensitivity of 75.00%, a
specificity of 81.80%, and an overall accuracy of 78.26%. Table 3.5 shows the confusion matrix for J48
classifier. The difference in overall accuracy between J48 and other classifiers was not statistically
significant due to the small sample size.
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Table 3.4 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the J48
classifier compared with other methods was assessed by significance testing (N = 23).
Classifier

Sensitivity
(%)

Specificity
(%)

J48
Logistic regression
KStar
Threshold selector
Multilayer perceptron

75.00
66.70
66.70
58.30
66.70

81.80
54.50
54.50
72.70
45.50

(Sensitivity+
Specificity)/2
(%)
78.40
60.60
60.60
65.50
56.10

Overall
Accuracy
(%)
78.26
60.86
60.86
65.21
56.52

P-value

<0.11
<0.11
<0.17
<0.06

Table 3.5 Confusion matrix obtained from the J48 classifier for predicting lymph node status using
the 9-gene signature.
Actual/Predicted
a (node negative)
b (node positive)

a (node negative)
9
3

b (node positive)
2
9

3.4.2 Time-dependent ROC analyses on data from Ried et al (n=73)
To explore whether the 9-gene lymph node signature could predict patient disease-free survival and
overall survival, the survival and status information along with the expression data of the 9 genes are used
for getting the time-dependent ROC plots. The accuracy of 5-year relapse-free survival prediction using
these 9 genes is 0.85 and 5-year overall survival prediction is 0.86, as represented by the AUC.

Figure 3.2 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and
overall survival using the 9-gene signature.
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3.4.3 Kaplan-Meier analyses on data from Ried et al (n=73)
The Cox model based on the expression of the 9-gene signature was used to get recurrence risk scores for
all the 73 patients. The choices for choosing a cut-off value for patient stratification are the peak value
from histogram, mean risk score or median risk score. In this analysis, the peak value from histogram was
chosen as cut-off as it resulted in best patient stratification. Cut-off values of 4.0 and 0.5 were chosen for
relapse-free survival and overall survival, respectively. The pamr package in R was used to plot the
Kaplan-Meier curves, for relapse-free survival and overall survival. The low-risk and high-risk groups
had distinct relapse-free survival (p = 1e-04, n=73, log-rank tests) and overall survival (p = 0.043, n=73,
log-rank tests).

Figure 3.3 Histograms of risk scores obtained from Cox model for relapse-free survival and overall
survival using the 9-gene signature.
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Figure 3.4 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall
survival using the 9-gene signature.
Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more
than 5 years and 10 patients experienced recurrence within 5 years after surgery. To test the performance
of the identified 9-gene signature, the subgroups obtained for the above group of 36 patients from the Cox
model were compared with their actual clinical outcomes. Table 3.6 shows the different parameters
obtained from the Cox model, using the 9-gene signature for relapse-free survival and overall survival,
respectively. Tables 3.7 and 3.8, show the comparison of predicted clinical outcome for patients with their
actual follow-up information, for relapse-free survival and overall survival, respectively. The Cox model
had a sensitivity of 60.0%, a specificity of 92.3%, and an overall accuracy of 83.3%, for predicting
relapse-free survival. In predicting overall survival, it had a sensitivity of 75.0%, a specificity of 45.8%,
and an overall accuracy of 59.0%.
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Table 3.6 Different parameters obtained from the Cox model using the 9-gene signature for
predicting relapse-free survival and overall survival.

Gene
Symbol
SNRPD3
IFRG28
PLXNB2
DC50
FLJ11078
MGC16044
RNF6
POU6F2
ITGB1

Relapse-free survival
exp
se
coef
(coef) (coef)
2.661
14.304 1.326
0.769
2.157
0.382
-3.121
0.044
1.305
-2.476
0.084
0.797
0.600
1.822
0.584
0.525
1.690
0.380
-1.163
0.312
0.815
0.869
2.384
1.179
1.612
5.013
1.237

zscore
2.006
2.012
-2.391
-3.107
1.028
1.382
-1.426
0.737
1.303

pvalue
0.045
0.044
0.017
0.001
0.300
0.170
0.150
0.460
0.190

coef
0.065
0.122
-0.516
-0.535
0.002
0.145
0.145
0.596
0.465

Overall survival
exp
se
z(coef) (coef) score
1.068
0.793 0.082
1.131
0.235 0.521
0.597
0.596 -0.866
0.586
0.459 -1.166
1.002
0.362 0.005
1.157
0.269 0.542
0.574
0.465 -1.193
1.816
0.581 1.026
1.592
0.603 0.771

pvalue
0.93
0.60
0.39
0.24
1.00
0.59
0.23
0.30
0.44

Table 3.7 Comparison of the sub groups predicted from the Cox model using the 9-gene signature
with the actual subgroups for relapse-free survival.

Recurrence
No recurrence

Recurrence
6
2

No recurrence
4
24

Sensitivity (%)

Specificity (%)

Overall accuracy (%)

60.0

92.3

83.3

Table 3.8 Comparison of the sub groups predicted from the Cox model using the 9-gene signature
with the actual subgroups for overall survival.

Death
Alive

Death
15
13

Alive
5
11

Sensitivity (%)

Specificity (%)

Overall accuracy (%)

75.0

45.8

59.0

The Cox model was used for stratifying all the 73 patients in Ried et al data, into low-risk and high-risk
groups, based on the 9-gene signature. Out of the 73 patients, a total of 37 did not have recurrence with
survival times less than 5 years. Twenty-nine patients had overall survival times less than 5 years without
any event (death). The relapse outcome for the 37 patients and the overall survival outcome for the 29
patients is currently unknown. Table 3.9 shows the prospective prognostic predictions of these patients
obtained from the Cox model for relapse-free survival and overall survival, respectively. The follow-up
information for these patients is being collected. When it becomes available in the future, the predictions
can be validated with it.
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Table 3.9 Patient subgroups obtained from the Cox model for relapse-free survival and overall
survival using the 9-gene signature.
Serial
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Patient ID
CC-P1
CC-P2
CC-P4
CC-P7
CC-P8
CC-P10
CC-P13
CC-P18
CC-P20
CC-P21
CC-P22
CC-P23
CC-P25
CC-P28
CC-P29
CC-P31
CC-P34
CC-P35
CC-P37
CC-P38
CC-P40
CC-P42
CC-P44
CC-P46
CC-P47
CC-P48
CC-P50
CC-P51
CC-P55
CC-P56
CC-P60
CC-P62
CC-P66
CC-P68
CC-P70
CC-P71
CC-P72

Predicted group by
Cox model (RFS)
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
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Patient ID
CC-P1
CC-P4
CC-P7
CC-P8
CC-P9
CC-P11
CC-P13
CC-P16
CC-P18
CC-P20
CC-P21
CC-P22
CC-P25
CC-P28
CC-P31
CC-P35
CC-P36
CC-P37
CC-P38
CC-P40
CC-P48
CC-P50
CC-P51
CC-P60
CC-P62
CC-P66
CC-P71
CC-P72
CC-P73

Predicted group by
Cox model (OS)
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
High Risk
High Risk
High Risk
Low Risk
High Risk
High Risk
High Risk
Low Risk
Low Risk
Low Risk
High Risk
High Risk
Low Risk
High Risk

3.4.4 External validation of the 9-gene signature on other colon cancer data
This part of the study sought to explore the extent to which the 9-gene signature could be used for
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets.
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation
technique on each of the independent datasets to find a suitable classification scheme for validation. Due
to the different number of attributes (matching genes), sample sizes and prediction variables one specific
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance.
The exact same set of classifiers could not be compared over all the validation datasets due to poor
performances of classifiers on some datasets and good performances on other datasets. The following
sections discuss the validation results and comparisons of various classifiers on the independent datasets
in detail.

3.4.4.1 Predicting lymph node status by leave-one-out cross validation on data from
Koinuma et al (n=17) PMID 16247484
The data from Koinuma et al (Affymetrix HG U133 A platform) consisted of 20 patient samples of which
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.10).
The data used for validation consisted of the expression of these 7 genes in the 17 patients. Weka
software was used for cross validation and the lymph node status (positive/negative) was predicted.
Different classification schemes including Naïve Bayes, LWL, JRip, Bagging, and KStar were applied to
this dataset to find the best scheme. Table 3.11 shows the comparison between Naïve Bayes and some of
the classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other
classifiers. It had a sensitivity of 100.00%, a specificity of 75.00%, and an overall accuracy of 82.35%.
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Table 3.12 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy
between Naïve Bayes and other classifiers was not statistically significant due to the small sample size.
Table 3.10 Matching genes in Koinuma et al data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
FLJ11078-hypothetical protein FLJ1107
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200016227
H200004174
H200015474
H200021334

Table 3.11 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve
Bayes classifier compared with other methods was assessed by significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

Naïve Bayes
LWL
JRip
Bagging
KStar

100.00
71.40
57.10
57.10
42.90

75.00
70.00
70.00
70.00
70.00

(Sensitivity+
Specificity)/2
(%)
87.50
70.70
63.55
63.55
56.45

Overall
Accuracy
(%)
82.35
70.58
64.70
64.70
58.82

P-value

< 0.21
< 0.13
< 0.13
< 0.07

Table 3.12 Confusion matrix obtained from the Naïve Bayes classifier for predicting lymph node
status using the 9-gene signature.
Actual/Predicted
a (node positive)
b (node negative)

a (node positive)
7
3

b (node negative)
0
7

3.4.4.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al
(n=18) PMID 16091735
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.13).
The data used for validation consisted of the expression of these 7 genes in the 18 patient samples. Weka
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes
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including Naïve Bayes, KStar, Multilayer perceptron, JRip, and Logistic regression were applied to this
dataset to find the best scheme. Table 3.14 shows the comparison between Naïve Bayes and some of the
classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other
classifiers. It had a sensitivity of 100.00%, a specificity of 88.90%, and an overall accuracy of 94.44%.
Table 3.15 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy
between Naïve Bayes and other classifiers was not statistically significant due to the small sample size.
Table 3.13 Matching genes in Barrier et al data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
FLJ11078-hypothetical protein FLJ1107
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200016227
H200004174
H200015474
H200021334

Table 3.14 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve Bayes
classifier compared with other methods was assessed by significance testing (N = 18).
Classifier

Sensitivity
(%)

Specificity
(%)

NaiveBayes
KStar
Multilayer perceptron
JRip
Logistic regression

100.00
100.00
88.90
88.90
88.90

88.90
66.70
77.80
66.70
66.70

(Sensitivity+
Specificity)/2
(%)
94.45
53.35
83.35
77.80
77.80

Overall
Accuracy
(%)
94.44
83.33
83.33
77.77
77.77

P-value

< 0.15
< 0.15
< 0.08
< 0.08

Table 3.15 Confusion matrix obtained from the Naïve Bayes classifier for predicting recurrence
using the 9-gene signature.
Actual/Predicted
a (recurrence)
b (no recurrence)

a (recurrence)
9
1

b (no recurrence)
0
8
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3.4.4.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al
(n=50) (PMID 16966692)
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.16).
The data used for validation consisted of the expression of these 7 genes in the 50 patient samples. Weka
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes
including Decision stump, Naïve Bayes, IB1, Logistic regression, and Multilayer perceptron were applied
to this dataset to find the best scheme. Table 3.17 shows the comparison between Decision stump and
some of the classifiers used for validation on other datasets. Decision stump classifier performed better
than the other classifiers. It had a sensitivity of 76.00%, a specificity of 88.00%, and an overall accuracy
of 82.00%. Table 3.18 shows the confusion matrix for Decision stump classifier. The difference in overall
accuracy between Decision stump and other classifiers was not statistically significant due to the small
sample size.
Table 3.16 Matching genes in Barrier et al data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
FLJ11078-hypothetical protein FLJ1107
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200016227
H200004174
H200015474
H200021334
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Table 3.17 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 9-gene signature. The improved overall accuracy of the prediction with the Decision
stump classifier compared with other methods was assessed by significance testing (N = 50).
Classifier

Sensitivity
(%)

Specificity
(%)

Decision stump
NaiveBayes
IB1
Logistic regression
Multilayer perceptron

76.00
68.00
84.00
68.00
68.00

88.00
92.00
64.00
72.00
72.00

(Sensitivity
+Specificity)/2
(%)
82.00
80.00
74.00
70.00
70.00

Overall
Accuracy
(%)
82.00
80.00
74.00
70.00
70.00

P-value

< 0.40
< 0.16
< 0.08
< 0.08

Table 3.18 Confusion matrix obtained from the Decision stump classifier for predicting recurrence
using the 9-gene signature.
Actual/Predicted
a (no recurrence)
b (recurrence)

a (no recurrence)
22
6

b (recurrence)
3
19

3.4.4.4 Predicting recurrence by leave-one-out cross validation on data from Barrier et al
(n=24) (PMID 17043639)
The data from Barrier et al (PMID 17043639) consisted of 22,283 genes and 24 patient samples. The
search for matching genes was done using the Affymetrix ids. There were 7 matching genes (Table 3.19).
The data used for validation consisted of the expression of these 7 genes in the 24 patient samples. Weka
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes
including Naïve Bayes, LWL, AD Tree, Random committee, and Multiboost AB were applied to this
dataset to find the best scheme. Table 3.20 shows the comparison between Naïve Bayes and some of the
classifiers used for validation on other datasets. Naive Bayes classifier performed better than the other
classifiers. It had a sensitivity of 50.00%, a specificity of 100.00%, and an overall accuracy of 79.16%.
Table 3.21 shows the confusion matrix for Naïve Bayes classifier. The difference in overall accuracy
between Naïve Bayes and other classifiers was not statistically significant due to the small sample size.
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Table 3.19 Matching genes in Barrier et al data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
FLJ11078-hypothetical protein FLJ1107
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200016227
H200004174
H200015474
H200021334

Table 3.20 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 9-gene signature. The improved overall accuracy of the prediction with the Naïve Bayes
classifier compared with other methods was assessed by significance testing (N = 24).
Classifier

Sensitivity
(%)

Specificity
(%)

NaiveBayes
LWL
AD Tree
Random committee
Multiboost AB

50.00
60.00
40.00
40.00
50.00

100.00
78.60
92.90
85.70
71.40

(Sensitivity
+Specificity)/2
(%)
75.00
69.30
66.45
62.85
60.70

Overall
Accuracy
(%)
79.16
70.83
70.83
66.66
62.50

P-value

< 0.26
< 0.26
< 0.17
< 0.11

Table 3.21 Confusion matrix obtained from the Naïve Bayes classifier for predicting recurrence
using the 9-gene signature.
Actual/Predicted
a (no recurrence)
b (recurrence)

a (no recurrence)
14
5

b (recurrence)
0
5

3.4.4.5 Predicting the response of cell lines in NCI-60 (n=34) (U133A GCRMA) data by
leave-one-out cross validation
This dataset 26 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search
for matching genes was done using the gene symbols. There were 5 matching genes (Table 3.22). The

26

http://discover.nci.nih.gov/cellminer/loadDownload.do
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data used for validation consisted of the expression of these 5 genes in the 34 cell lines. Weka software
was used for validation and the response (sensitive/resistant) to the drug 5-FU (fluorouracil) was
predicted. Different classification schemes including Threshold selector, IB1, Logistic regression,
Random Tree, and Multilayer perceptron were applied to this dataset to find the best scheme. Table 3.23
shows the comparison between Threshold selector and some of the classifiers used for validation on other
datasets. Threshold selector performed better than the other classifiers. It had a sensitivity of 94.10%, a
specificity of 76.50%, and an overall accuracy of 85.29%. Table 3.24 shows the confusion matrix for
Threshold selector classifier. The difference in overall accuracy between Threshold selector and IB1 (p <
0.01), Logistic regression (p < 0.01), Random Tree (p < 0.01), Multilayer perceptron (p < 0.01) was
statistically significant.
Table 3.22 Matching genes in NCI-60 U133A data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
PLXNB2-plexin B2, mRNA
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200000861
H200004174
H200015474
H200021334

Table 3.23 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 9-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
IB1
Logistic regression
Random Tree
Multilayer perceptron

94.10
58.80
52.90
47.10
35.30

76.50
52.90
47.10
52.90
41.20
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(Sensitivity
+Specificity)/2
(%)
85.30
55.85
50.00
50.00
38.25

Overall
Accuracy
(%)
85.29
55.88
50.00
50.00
38.23

P-value

< 0.01
< 0.01
< 0.01
< 0.01

Table 3.24 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 9-gene signature.
Actual/Predicted
a (sensitive)
b (resistant)

a (sensitive)
16
4

b (resistant)
1
13

3.4.4.6 Predicting the response of cell lines in NCI-60 (n=34) (U133B GCRMA) data by
leave-one-out cross validation
This dataset 27 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for
matching genes was done using the gene symbols. There was 1 matching gene (Table 3.25). The data
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted.
Different classification schemes including Threshold selector, Random Tree, Random committee,
Decision stump, and AD Tree were applied to this dataset to find the best scheme. Table 3.26 shows the
comparison between Threshold selector and some of the classifiers used for validation on other datasets.
Threshold selector performed better than the other classifiers. It had a sensitivity of 82.40%, specificity of
76.50%, and an overall accuracy of 79.41%. Table 3.27 shows the confusion matrix for Threshold
selector classifier. The difference in overall accuracy between Threshold selector and Random tree (p <
0.02), Random committee (p < 0.02), Decision stump (p < 0.01), AD Tree (p < 0.01) was statistically
significant.
Table 3.25 Matching genes in NCI-60 U133B data.
GENE NAME
POU6F2-POU domain, class 6,transcript

27

ID
H200015474

http://discover.nci.nih.gov/cellminer/loadDownload.do
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Table 3.26 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 9-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
Random Tree
Random committee
Decision stump
AD Tree

82.40
64.70
64.70
94.10
52.90

76.50
47.10
47.10
11.80
47.10

(Sensitivity
+Specificity)/2
(%)
79.45
55.90
55.90
52.95
50.00

Overall
Accuracy
(%)
79.41
55.88
55.88
52.94
50.00

P-value

< 0.02
< 0.02
< 0.01
< 0.01

Table 3.27 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 9-gene signature.
Actual/Predicted
a (sensitive)
b (resistant)

a (sensitive)
14
4

b (resistant)
3
13

3.4.5 Summary of validation results of 9-gene signature
Table 3.28 shows the details of different validation datasets, predicted variables, classifiers used and
different accuracies obtained using the 9-gene signature. For each dataset the classifier with the highest
overall accuracy was reported.
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Table 3.28 Summary of validation results of 9-gene signature on Ried et al data, independent colon
cancer datasets and NCI-60 data.
Dataset

Classifier

Predicted
variable

Sensitivity
(%)

Specificity
(%)

(Sensitivity +
Specificity)/2
(%)

Overall
accuracy
(%)

Ried et al testing set
(n=23)

J48

Lymph
node status

75.00

81.80

78.40

78.26

Naïve
Bayes

Lymph
node status

100.00

75.00

87.50

82.35

Naïve
Bayes

Recurrence

100.00

88.90

94.45

94.44

Decision
stump

Recurrence

76.00

88.00

82.00

82.00

Naïve
Bayes

Recurrence

50.00

100.00

75.00

79.16

94.10

76.50

85.30

85.29

82.40

76.50

79.45

79.41

PMID 17210682

Koinuma et al
(n=17)
PMID 16247484
Barrier et al
(n=18)
PMID 16091735
Barrier et al
(n=50)
PMID 16966692
Barrier et al
(n=24)
PMID 17043639
NCI 60 U133A
(n=34)

Threshold
selector

NCI 60 U133B
(n=34)

Threshold
selector

Drug
response
(5-FU)
Drug
response
(5-FU)

3.5 Correlation analysis on CGH and RNA data
3.5.1 Description of the data sets
CGH (Comparative genomic hybridization) data: The array CGH data was available only for 29 of the
73 patient samples. The data consisted of probe name, chromosome name, start and stop coordinates,
feature number, and description of the genes.
RNA (Ribonucleic acid) data: The RNA data consisted of 22,464 genes and 73 tumor samples.

3.5.2 Correlation coefficient analysis on the 9-gene signature
This study focused on identifying genes in the 9-gene signature whose cDNA copy number was
correlated with the RNA expression data. The CGH data was checked for matching genes with the 9-gene
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signature and 89 matched probes were found. The same 29 patient samples available in the array CGH
data were selected from RNA data. The 9-gene signature and 29 sample RNA expression data versus 9gene signature and 29 sample CGH data was used to compute the correlation coefficient for each of the
genes. After computing the correlation coefficient for each of the matching gene pairs, the genes with
absolute value of correlation coefficient > 0.36 were considered to be significant (p < 0.05). The gene
ITGB1 satisfied this condition and Table 3.29 shows the details. These genes might be helpful in
identifying the regulators of gene expression.
Table 3.29 Genes with correlation coefficient > 0.36 in the CGH versus RNA data.
Probe name

Chromosome
name

Start
location

Stop
location

Feature
number

Gene
symbol

Correlation
coefficient

A_14_P128618

10

33274603

33274662

22571

ITGB1

0.4767

A_14_P201824

10

33284494

33284553

22255

ITGB1

0.4321

3.5.3 Genome wide correlation analysis on CGH and RNA data
Our aim was to identify the cDNA copy numbers of the genes that were correlated with RNA expression
data. The 29 tumor samples that were available in the CGH data were selected from the RNA data for the
analysis. The genes in the CGH data were matched with the genes in the RNA data. Correlation
coefficient was calculated for each of these matched gene pairs across the 29 tumor samples. The
obtained correlation coefficients for each of the genes were converted to their absolute values, and all
genes which with correlation coefficient values < 0.36 were removed. From the remaining set of genes, 3
or more different consecutive genes were selected. Table 3.30 shows in detail the identified genes. The
chromosome locations of these genes might be important in identifying the regulators of gene expression.
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Table 3.30 Details of the genes identified by genome-wide correlation analysis.
Chromosome
name

Start

Stop

Feature
number

Number of
consecutive
genes

Consecutive genes (count)

1

11788695

11788743

144635

6

MTHFR (2) CLCN6 (4)

1

23864785

23864839

162971

5

LYPLA2 (1) GALE (1) MGCL (3)

1

35990614

35990665

51144

6

EIF2C4 (1) EIF2C1 (5)

1

94617936

94617995

64611

10

1

1.13E+08

1.13E+08

79186

3

MOV10 (1)

9

1.09E+08

1.09E+08

4486

5

ACTL7A (1)

9

1.24E+08

1.24E+08

1752

6

NEK6 (1)

9

1.37E+08

1.37E+08

81538

3

MGC14141 (2)

11

18374755

18374806

146020

3

LDHA (2)

LDHC (1)

12

54789993

54790052

78424

3

PA2G4 (1)

RPL41 (2)

14

75183472

75183531

75020

3

C14orf58 (1)

14

95918447

95918506

126315

6

16

23557994

23558053

42174

3

FLJ21816 (1)

17

7232718

7232766

159975

3

TNK1 (2)

17

18160066

18160125

44369

5

SMCR8 (1)

17

35087534

35087593

67698

8

20

17499809

17499868

161401

5

DSTN (4)

20

32972022

32972071

118483

5

ACAS2 (2)

20

34697094

34697153

63618

8

SLA2 (2)

20

43442415

43442474

29649

7

C20orf35 (5)

20

60315571

60315630

19595

4

ADRM1 (2)

LAMA5 (2)

21

26011625

26011684

70488

6

ATP5J (3)

GABPA (3)

X

48506958

48507011

181787

3

TIMM17B (2)
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ABCD3 (8)

F3 (2)
RHOC (2)

IKBKAP (4)
PSMB7 (5)
KIAA1984 (1)

C14orf1 (2)

C14orf129 (1)

AK7 (5)
MGC3248 (2)

PLSCR3 (1)
SHMT1 (4)

PERLD1 (2) ERBB2 (5) C17orf37 (1)
RRBP1 (1)
GSS (3)
NDRG3 (6)
PIGT (2)

PQBP1 (1)

3.6 Summary
In this chapter, we identified a 9-gene signature to predict lymph node metastasis in colon cancer patients
based on the microarray gene expression data. This was achieved by, firstly preprocessing the data to
discard undifferentiated genes using the t-test, secondly replacing missing values with the k-nearest
neighbors algorithm, and thirdly applying variable selection using random forests. In the next step, the
genes without differential expression in lymph node negative versus positive tumors were removed in
order to retain only the discriminator genes and obtained the 9-gene signature. The Kaplan-Meier plots of
the 9-gene signature on Ried et al data (n=73) generated significant patient stratification into, low-risk
and high-risk groups (log-rank tests, p < 0.05), with distinct relapse-free survival (RFS) and overall
survival (OS). Out of the 73 patients in Ried et al data, 26 patients remained relapse-free for more than 5
years and 10 patients experienced relapse within 5 years after surgery. In these patients, the Cox model
had a sensitivity of 60.0% and a specificity of 92.3%. The 9-gene lymph node signature was cross
validated on independent colon cancer data sets. The drug response to 5-FU (fluorouracil) on the NCI-60
cell line data was predicted. Our results showed that it is feasible to predict the lymph node status of the
patients with the 9-gene signature and it might be used for tailored treatments for patients in the high-risk
group. Correlation analysis was done between the CGH and RNA data using the 14 gene signature and
the gene ITGB1 was identified which exhibited strong relationship between the two groups. Genome
wide correlation analysis was done to identify DNA copy numbers of the genes that were correlated with
RNA expression data. These results might be useful in identifying the regulators of gene expression.
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Chapter 4
Prediction models for recurrence in colon cancer
4.1 Introduction
Recurrence or relapse is the reappearance of a tumor or the return of symptoms after treating for cancer.
Postoperative treatment given to Duke’s stage B and Duke’s stage C colon cancer patients is highly
debatable (24). It is uncertain whether adjuvant chemotherapy should be given to Duke’s stage B patients
because not all the patients benefit from it. So, there is a need to identify patients at high-risk of
recurrence who would develop relapse in the Duke’s B group so that they can be given aggressive
treatment, and patients at low-risk of recurrence would be spared from the invasive treatment. Our study
aims at identifying patients at low and high-risks of recurrence by building prognostic models for stage II
(Duke’s stage B) and stage III (Duke’s stage C) colon cancer patients.
The training set comprised of 36 patients (10 patients having recurrence within 5 years after
surgery and 26 patients remaining relapse free for more than 5 years). The remaining 37 patients formed
the testing set. The missing values in the gene expression data were replaced using the k-nearest
neighbors algorithm with k=30. A combinatorial scheme was used to identify biomarkers predicting the
recurrence. In the first step, variable selection using random forests was applied on the training set and a
4-gene subset was obtained. In the second step, InfoGain feature selection technique was applied to
further reduce the dimensionality by dropping lower ranked genes, and hence obtained the 3-gene
signature. The same procedure was repeated again by replacing missing values in the preprocessed data
with k-nearest neighbors algorithm (k=20) and obtained the 5-gene signature.
The performance of these signatures was evaluated by cross validation on independent colon
cancer data sets. The discriminatory powers of the identified gene signatures were evaluated by the timedependent ROC technique, and these signatures could effectively stratify patients into low-risk and high52

risk groups. Prediction models were built with the 3-gene signature and the 5-gene signature using
classifiers in Weka software to predict recurrence in patients from the testing set. These gene signatures
were also cross validated on independent colon cancer datasets to evaluate their performance.
The remainder of this chapter is organized as follows. Section 4.2 introduces our study design and
describes the experiment in detail. Section 4.3 describes the validation results. Section 4.4 discusses the
study design of 5-gene signature and describes the experiment in detail. Section 4.5 describes the
validation results. Section 4.6 compares the 3-gene and 5-gene signatures, and Section 4.7 provides a
summary of this chapter.
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4.2 Study Design for the 3-gene signature
Colon cancer data from Ried et al (n=73)

Applying t-test on genes having > 5 missing values to determine differential gene
expression in lymph node negative versus positive patients

Selecting genes passing t-test and all other genes
with ≤ 5 missing values

Splitting data into training (n=36) and testing sets (n=37)

Missing value replacement using knn
algorithm on training set (k=30)

Applying random forests using VarSelRF
package using R software

4-gene signature

Using Infogain attribute selection in Weka to discard the
gene with lowest rank (LOC114659-KIAA0563)

3-gene signature

Validation on Ried et al data, plotting Timedependent ROC and Kaplan Meier plots

Building recurrence prediction model and cross validation
on other colon cancer datasets

Figure 4.1 Block diagram of the study for 3-gene signature.
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4.2.1 Experimental procedure
Data Source The colon cancer microarray data from Ried et al. (13) contained 22,464 genes and 73
patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples
were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive).
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a
specific channel. Dividing one intensity by the other gives the expression ratio. We used log ratios as they
are lot easier to work with than the regular ratios. The log ratio (532/635) was considered for this analysis.
It is the log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm.
Data Preprocessing-t test We investigated whether the observed difference between the two groups
(node positive versus negative) represents a real difference in the total study population from which the
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test. The
number of missing values for each gene was found and t-test was done on genes with more than 5 missing
values to evaluate the difference in the proportions of missing values in node positive versus negative
groups. The genes passing the t-test (p < 0.05, two-sided) along with all other genes were selected for
further processing. A total of 10,220 genes satisfied this condition.
Training dataset The training dataset consisted of the patient samples having recurrence within 5 years
after surgery, survival time ≥ 60 months selected based on the clinical data available for the dataset. The
expression data of the 10,220 genes and 36 patients, constituted the training set. The remaining patients
formed the testing set.
Missing value replacement The training dataset contained missing values. They were replaced using the
EMV

28

package in R software with k=30. This technique estimates the missing values based on the k-

nearest neighbors algorithm. This algorithm selects the k nearest rows that do not contain any missing

28

http://cran.r-project.org/web/packages/EMV/index.html
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values to the one containing at least one missing value based on the Euclidian distance. Then the missing
values are replaced by the average of the neighbors.
Biomarker identification VarSelRF 29 package in R was used in a series of steps on the training dataset
to find the important features. The recurrence status was used as the class variable. In the first step, a
forest with N trees was built and the features were ranked according to the importance of the variables. In
the second step, 20% of the variables that were least important were removed and a new forest was
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the
fitted random forests were examined and a set of 4 genes leading to the smallest error rate were selected.
InfoGain attribute selection technique was applied to drop the least ranked gene, LOC114659--KIAA0563,
giving us the 3-gene signature. Table 4.1 shows the 3-gene signature.
Table 4.1 The 3-gene signature for predicting colon cancer recurrence.
GENE NAME
LRRC14-leucine rich repeat containing
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

29

ID
H200014103
H200012309
H200006643

http://cran.r-project.org/web/packages/varSelRF/index.html
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4.3 Results
4.3.1 Building prediction model using Weka
The training set consisted of expression data of the 3-gene signature in 36 patients (10 patients having
recurrence within 5 years after surgery and 26 patients having survival time more than 5 years without
recurrence). The remaining patients formed the testing set. Weka software was used for 10 fold cross
validation on the training dataset. Different classification schemes in Weka were applied to this dataset to
find the best scheme. Table 4.2 shows the top five classifiers including LWL, AD Tree, Multialyer
perceptron, IB1, and Logistic regression based on their prediction accuracies. LWL classifier performed
better than the other classifiers. It had a sensitivity of 80.00%, a specificity of 96.20%, and an overall
accuracy of 91.66%. Table 4.3 shows the confusion matrix for LWL classifier. The difference in overall
accuracy between LWL and other classifiers was not statistically significant due to the small sample size.
The LWL classifier model was saved and used to predict class (recurrence/no recurrence) for patients in
the testing set. Table 4.4 shows the predicted class for patients in the testing set using the LWL model and
compares it with the class predictions obtained from the Cox model.
Table 4.2 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 3-gene signature. The improved overall accuracy of the prediction with the LWL
classifier compared with other methods was assessed by significance testing (N = 36).
Classifier

Sensitivity
(%)

Specificity
(%)

LWL
AD Tree
Multilayer perceptron
IB1
Logistic regression

80.00
60.00
60.00
40.00
30.00

96.20
96.20
92.30
92.30
96.20

(Sensitivity
+Specificity)/2
(%)
88.10
78.10
76.15
66.15
63.10

Overall
accuracy
(%)
91.66
83.33
83.33
77.77
77.77

P-value

< 0.14
< 0.14
< 0.06
< 0.06

Table 4.3 Confusion matrix obtained from the LWL classifier for predicting recurrence using the 3gene signature.
Actual/Predicted
a (recurrence)
b (no recurrence)

a (recurrence)
8
1

b (no recurrence)
2
25
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Table 4.4 Predicting recurrence in patients from the testing dataset using the 3-gene signature.
Serial
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Patient
Number
CC-P1
CC-P2
CC-P4
CC-P7
CC-P8
CC-P10
CC-P13
CC-P18
CC-P20
CC-P21
CC-P22
CC-P23
CC-P25
CC-P28
CC-P29
CC-P31
CC-P34
CC-P35
CC-P37
CC-P38
CC-P40
CC-P42
CC-P44
CC-P46
CC-P47
CC-P48
CC-P50
CC-P51
CC-P55
CC-P56
CC-P60
CC-P62
CC-P66
CC-P68
CC-P70
CC-P71
CC-P72

Prediction by
LWL
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
Recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
Recurrence
Recurrence
Recurrence

Prediction by
Cox model
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
Recurrence
Recurrence
Recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
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Match
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
-

4.3.2 Plotting Kaplan-Meier curves based on the patient subgroups obtained from
LWL prediction model on data from Ried et al (n=73) using the 3-gene signature
The LWL recurrence prediction model discussed in the previous section generated two subgroups of
patients, no recurrence and recurrence, on the training and testing data sets. Kaplan-Meier curves were
plotted based on the expression data of 3-gene signature in the 73 patient samples (Ried et al data) and the
patient subgroups obtained from LWL prediction model. The Kaplan-Meier plots generated significant
patient stratification into no recurrence and recurrence groups (p < 0.05, n=73, log-rank tests), with
distinct relapse-free survival. Figure 4.2 shows the survival probabilities for each of the patient subgroups
for relapse-free survival.

Figure 4.2 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival using the 3gene signature based on the patient subgroups obtained from LWL recurrence prediction model.

4.3.3 Time-dependent ROC analyses data from Ried et al (n=73)
To explore whether the 3-gene recurrence signature could predict patient disease-free survival and overall
survival, the survival and status information along with the expression data of the 3 genes were used for
getting the time-dependent ROC curves. The accuracy of 5-year relapse-free survival prediction using
these 3 genes is 0.80 and 5-year overall survival prediction is 0.79, as represented by the AUC.
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Figure 4.3 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and
overall survival using the 3-gene signature.

4.3.4 Kaplan-Meier analyses on data from Ried et al (n=73)
The Cox model based on the expression of the 3-gene signature was used to get recurrence risk scores for
all the 73 patient samples. The choices for choosing a cut-off value for patient stratification are the peak
value from histogram, mean risk score or median risk score. In this analysis, the peak value from
histogram was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 2.0 and 1.0
were chosen for relapse-free survival and overall survival, respectively. The pamr package in R was used
to plot the relapse-free survival probability of low-risk and high-risk groups. The low-risk and high-risk
groups had distinct relapse-free survival (p = 1e-04, n=73, log-rank tests). The low-risk and high-risk
groups had distinct overall survival (p = 0.011, n=73, log-rank tests).
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Figure 4.4 Histograms of risk scores obtained from Cox model for relapse-free survival and overall
survival using the 3-gene signature

Figure 4.5 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall
survival using the 3-gene signature

Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more
than 5 years and 10 patients had recurrence within 5 years after surgery. To test the performance of the 3gene signature, the subgroups obtained for the above group of 36 patients from the Cox model were
compared with their actual clinical outcomes. Table 4.5 shows the different parameters obtained from
Cox model using the 3-gene signature, for relapse-free survival and overall survival, respectively. Tables
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4.6 and 4.7, show the comparison of predicted clinical outcome for patients with their actual follow-up
information, for relapse-free survival and overall survival, respectively. The Cox model had a sensitivity
of 80.0%, a specificity of 96.1%, and an overall accuracy of 91.7%, for predicting relapse-free survival.
In predicting overall survival, it had a sensitivity of 40.0%, a specificity of 95.9%, and an overall
accuracy of 70.4%.
Table 4.5 Different parameters obtained from Cox model using the 3-gene signature for relapsefree survival and overall survival
Gene
Symbol
LRRC14
E2F2
SLC25A5

Relapse-free survival
exp
se
coef
(coef)
(coef)
0.449
1.647
0.529
-1.500
0.223
0.586
0.375
1.455
0.216

zscore
0.943
-2.561
1.738

pvalue
0.350
0.010
0.082

coef
0.213
-0.666
0.081

Overall survival
exp
se
zp(coef) (coef) score value
1.238 0.376 0.568 0.570
0.513 0.335 -1.988 0.047
1.085 0.179 0.455 0.650

Table 4.6 Comparison of the sub groups predicted from the Cox model using the 3-gene signature
with the actual subgroups for relapse-free survival

Recurrence
No recurrence

Recurrence
8
1

No recurrence
2
25

Sensitivity (%)

Specificity (%)

Overall accuracy (%)

80.0

96.1

91.7

Table 4.7 Comparison of the sub groups predicted from the Cox model using the 3-gene signature
with the actual subgroups for overall survival
Death
Alive

Death
8
1

Alive
12
23

Sensitivity (%)

Specificity (%)

Overall accuracy (%)

40.0

95.9

70.4

The Cox model was used for stratifying all the 73 patient samples in Ried et al data into low-risk and
high-risk groups, based on the 3-gene signature. Out of the 73 patients, a total of 37 patients had no
recurrence with survival times less than 5 years. Twenty-nine patients had overall survival times less than
5 years without any event (death). The relapse outcome for the 37 patients and the overall survival
outcome for the 29 patients is currently unknown. Table 4.8 shows the prospective prognostic predictions
of these patients obtained from the Cox model for relapse-free survival and overall survival, respectively.
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The follow-up information for these patients is being collected. When it becomes available in the future,
the predictions can be validated with it.
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Table 4.8 Patient subgroups obtained from the Cox model for relapse-free survival using the 3-gene
signature
Serial
Number

Patient ID

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

CC-P1
CC-P2
CC-P4
CC-P7
CC-P8
CC-P10
CC-P13
CC-P18
CC-P20
CC-P21
CC-P22
CC-P23
CC-P25
CC-P28
CC-P29
CC-P31
CC-P34
CC-P35
CC-P37
CC-P38
CC-P40
CC-P42
CC-P44
CC-P46
CC-P47
CC-P48
CC-P50
CC-P51
CC-P55
CC-P56
CC-P60
CC-P62
CC-P66
CC-P68
CC-P70
CC-P71
CC-P72

Predicted group by
Cox model (RFS)
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
High Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
High Risk
High Risk
High Risk
High Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
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Patient ID
CC-P1
CC-P4
CC-P7
CC-P8
CC-P9
CC-P11
CC-P13
CC-P16
CC-P18
CC-P20
CC-P21
CC-P22
CC-P25
CC-P28
CC-P31
CC-P35
CC-P36
CC-P37
CC-P38
CC-P40
CC-P48
CC-P50
CC-P51
CC-P60
CC-P62
CC-P66
CC-P71
CC-P72
CC-P73

Predicted group by
Cox model (OS)
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk

4.3.5 Independence of 3-gene recurrence signature of tumor stage
Improved prediction of recurrence can profoundly affect clinical decisions. However, following the
current clinical guidelines, few of the lymph node-negative patients (stage II) are offered adjuvant
chemotherapy. Because 25% to 40% of the patients would develop tumor relapse, the prognosis signature
can be a powerful tool to select the patients who are at high-risk and ensure that they receive adjuvant
treatment. This part of the study was focused on verifying if the recurrence predictions obtained on Ried
et al data were statistically significant when validated separately in Stage II and Stage III patients. It was
seen that the 3-gene signature could stratify the patients into low-risk and high-risk groups in Stage II and
Stage III samples individually with distinct relapse-free survival. The patient subgroups were obtained
based on the Cox model. The patients belonging to the low-risk group had higher survival probabilities
than those belonging to the high-risk group. Based on the predictions from LWL model using the 3-gene
signature, Kaplan-Meier plots were plotted in Stage II and Stage III samples separately. But the patient
stratification was not statistically significant and the results were not reported. So it can be said that Cox
model is the best model for predicting recurrence using the 3-gene signature. These results confirm that
the 3-gene recurrence signature might be applicable to prognostic categorization for the clinical
management of colon cancer.

Figure 4.6 The 3-gene signature stratifies patients in Stage II tumors and Stage III tumors into
distinct low-risk and high-risk groups for relapse-free survival based on the Cox model.
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4.3.6 External validation of the 3-gene signature on other colon cancer data
This part of the study sought to explore the extent to which the 3-gene signature could be used for
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets.
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation
technique on each of the independent datasets to find a suitable classification scheme for validation. Due
to the different number of attributes (matching genes), sample sizes and prediction variables one specific
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance.
The exact same set of classifiers could not be compared over all the validation datasets due to poor
performances of classifiers on some datasets and good performances on other datasets. The following
sections discuss the validation results and comparisons of various classifiers on the independent datasets
in detail.

4.3.6.1 Predicting lymph node status by leave-one-out cross validation on data from
Koinuma et al. (n=17) (PMID 16247484)
The data from Koinuma et al (Affymetrix HG U133 A platform) consisted of 20 patient samples of which
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The
search for matching genes with the 3-gene signature was done using the Affymetrix ids. There were 3
matching genes (Table 4.9). The data used for validation consisted of the expression of these 3 genes in
the 17 patient samples. Weka software was used for validation and lymph node status (positive/negative)
was predicted. Different classification schemes including Multilayer perceptron, Decision stump, Logistic
regression, JRip, and Adaboost M1 were applied to this dataset to find the best scheme. Table 4.10 shows
the comparison between Multilayer perceptron and some of the classifiers used for validation on other
datasets. Multilayer perceptron classifier performed better than the other classifiers. It had a sensitivity of
71.40%, a specificity of 90.00%, and an overall accuracy of 82.35%. Table 4.11 shows the confusion
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matrix for Multilayer perceptron classifier. The difference in overall accuracy between Multilayer
perceptron and other classifiers was not statistically significant due to the small sample size.
Table 4.9 Matching genes in Koinuma et al data
GENE NAME
LRRC14-leucine rich repeat containing
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

ID
H200014103
H200012309
H200006643

Table 4.10 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 3-gene signature. The improved overall accuracy of the prediction with the
Multilayer perceptron classifier compared with other methods was assessed by significance testing
(N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

Multilayer perceptron
Decision stump
Logistic regression
JRip
Adaboost M1

71.40
42.90
57.10
14.30
28.60

90.00
100.00
80.00
100.00
80.00

(Sensitivity+
Specificity)/2
(%)
80.70
71.45
68.55
57.15
54.30

Overall
Accuracy
(%)
82.35
76.47
70.58
64.70
58.82

P-value

< 0.33
< 0.21
< 0.13
< 0.06

Table 4.11 Confusion matrix obtained from the Multilayer perceptron classifier for predicting
lymph node status using the 3-gene signature.
Actual/Predicted
a (positive)
b (negative)

a (positive)
5
1

b (negative)
2
9

4.3.6.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al.
(n=18) (PMID 16091735)
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The
search for matching genes with the 3-gene signature was done using the Affymetrix ids. There were 3
matching genes (Table 4.12). The data used for validation consisted of the expression of these 3 genes in
the 18 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted.
Different classification schemes including Threshold selector, AdaboostM1, LWL, Multilayer perceptron,
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and IB1 were applied to this dataset to find the best scheme. Table 4.13 shows the comparison between
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector
classifier performed better than the other classifiers. It had a sensitivity of 88.90%, a specificity of
77.80%, and an overall accuracy of 83.33%. Table 4.14 shows the confusion matrix for Threshold
selector classifier. The difference in overall accuracy between Threshold selector and other classifiers was
not statistically significant due to the small sample size.
Table 4.12 Matching genes in Barrier et al data.
GENE NAME
LRRC14-leucine rich repeat containing
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

ID
H200014103
H200012309
H200006643

Table 4.13 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 3-gene signature. The improved overall accuracy of the prediction with the Threshold
selector classifier compared with other methods was assessed by significance testing (N = 18).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
AdaboostM1
LWL
Multilayer perceptron
IB1

88.90
77.80
77.80
77.80
66.70

77.80
77.80
77.80
66.70
66.70

(Sensitivity+
Specificity)/2
(%)
83.35
77.80
77.80
72.25
66.70

Overall
Accuracy
(%)
83.33
77.77
77.77
72.22
66.66

P-value

< 0.34
< 0.34
< 0.22
< 0.13

Table 4.14 Confusion matrix obtained from the Threshold selector classifier for predicting
recurrence using the 3-gene signature
Actual/Predicted
a (recurrence)
b (no recurrence)

a (recurrence)
8
2

b (no recurrence)
1
7

4.3.6.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al.
(n=50) (PMID 16966692)
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The
search for matching genes with the 3-gene signature was done using the Affymetrix ids. There were 3
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matching genes (Table 4.15). The data used for validation consisted of the expression of these 3 genes in
the 50 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted.
Different classification schemes including IB1, LWL, Multilayer perceptron, Random committee, and
AdaboostM1 were applied to this dataset to find the best scheme. Table 4.16 shows the comparison
between IB1 and some of the classifiers used for validation on other datasets. IB1 classifier performed
better than the other classifiers. It had a sensitivity of 76.00%, a specificity of 80.00%, and an overall
accuracy of 78.00%. Table 4.17 shows the confusion matrix for IB1 classifier. The difference in overall
accuracy between IB1 and other classifiers was not statistically significant due to the small sample size.
Table 4.15 Matching genes in Barrier et al data.
GENE NAME
LRRC14-leucine rich repeat containing
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

ID
H200014103
H200012309
H200006643

Table 4.16 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 3-gene signature. The improved overall accuracy of the prediction with the IB1 classifier
compared with other methods was assessed by significance testing (N = 50).
Classifier

Sensitivity
(%)

Specificity
(%)

IB1
LWL
Multilayer perceptron
Random committee
AdaboostM1

76.00
68.00
80.00
68.00
56.00

80.00
84.00
68.00
72.00
80.00

(Sensitivity+
Specificity)/2
(%)
78.00
76.00
74.00
70.00
68.00

Overall
Accuracy
(%)
78.00
76.00
74.00
70.00
68.00

P-value

< 0.41
< 0.32
< 0.18
< 0.12

Table 4.17 Confusion matrix obtained from the IB1 classifier for predicting recurrence using the 3gene signature.
Actual/Predicted
a (no recurrence)
b (recurrence)

a (no recurrence)
20
6

b (recurrence)
5
19
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4.3.6.4 Predicting the response of cell lines in NCI-60 (U133A GCRMA) data (n=34) by
leave-one-out cross validation on data
This dataset 30 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search
for matching genes was done using the gene symbols. There were 3 matching genes (Table 4.18). The
data used for validation consisted of the expression of these 3 genes in the 34 cell lines. Weka software
was used for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was
predicted. Different classification schemes including Threshold selector, Multilayer perceptron, IB1,
LWL, and Logistic regression were applied to this dataset to find the best scheme. Table 4.19 shows the
comparison between Threshold selector and some of the classifiers used for validation on other datasets.
Threshold selector classifier performed better than the other classifiers. It had a sensitivity of 94.10%, a
specificity of 88.20%, and an overall accuracy of 91.17%. Table 4.20 shows the confusion matrix for
Threshold selector classifier. The difference in overall accuracy between Threshold selector and
Multilayer perceptron (p < 0.01), IB1 (p < 0.01), LWL (p < 0.01), Logistic regression (p < 0.01) was
statistically significant.
Table 4.18 Matching genes in NCI-60 U133A data.
GENE NAME
LRRC14-leucine rich repeat containing
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

30

ID
H200014103
H200012309
H200006643

http://discover.nci.nih.gov/cellminer/loadDownload.do
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Table 4.19 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 3-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
Multilayer perceptron
IB1
LWL
Logistic regression

94.10
70.60
64.70
82.40
35.30

88.20
41.20
47.10
29.40
58.80

(Sensitivity+
Specificity)/2
(%)
91.15
55.90
55.90
55.90
47.05

Overall
Accuracy
(%)
91.17
55.88
55.88
55.88
47.05

P-value

< 0.01
< 0.01
< 0.01
< 0.01

Table 4.20 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 3-gene signature.
Actual/Predicted
a (sensitive)
b (resistant)

a (sensitive)
16
2

b (resistant)
1
15

4.3.6.5 Predicting the response of cell lines in NCI-60 (U133B GCRMA) data (n=34) by
leave-one-out cross validation on data
This dataset 31 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for
matching genes was done using the gene symbols. There was 1 matching gene (Table 4.21). The data
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted.
Different classification schemes including Threshold selector, IB1, Multilayer perceptron, LWL, and
Bagging were applied to this dataset to find the best scheme. Table 4.22 shows the comparison between
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector
classifier performed better than the other classifiers. It had a sensitivity of 88.23%, a specificity of

31

http://discover.nci.nih.gov/cellminer/loadDownload.do
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88.23%, and an overall accuracy of 88.23%. Table 4.23 shows the confusion matrix for Threshold
selector classifier. The difference in overall accuracy between Threshold selector and IB1 (p < 0.01),
Multilayer perceptron (p < 0.01), LWL (p < 0.01), Bagging (p < 0.01) was statistically significant.
Table 4.21 Matching genes in NCI-60 U133B data.
GENE NAME
E2F2-E2F transcription factor 2 (E2F2)

ID
H200012309

Table 4.22 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 3-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
IB1
Multilayer perceptron
LWL
Bagging

88.23
47.10
11.80
29.40
35.30

88.23
52.90
82.40
58.80
47.10

(Sensitivity+
Specificity)/2
(%)
88.23
50.00
47.10
44.10
41.20

Overall
Accuracy
(%)
88.23
50.00
47.05
44.11
41.17

P-value

< 0.01
< 0.01
< 0.01
< 0.01

Table 4.23 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 3-gene signature.
Actual/Predicted
a (sensitive)
b (resistant)

a (sensitive)
15
2

b (resistant)
2
15
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4.3.7 Summary of validation results of 3-gene signature
Table 4.24 shows the details of different validation datasets, predicted variables, classifiers used and
different accuracies obtained using the 3-gene signature. For each dataset the classifier with the highest
overall accuracy was reported.
Table 4.24 Summary of validation results of 3-gene signature on Ried et al data, independent colon
cancer datasets and NCI 60 data.
Dataset

Classifier

Predicted
variable

Sensitivity
(%)

Specificity
(%)

(Sensitivity +
Specificity)/2
(%)

Overall
accuracy
(%)

LWL

Recurrence

80.00

96.20

88.10

91.66

Ried et al training set
(n=36)
PMID 17210682
Ried et al training set
(n=36)
PMID 17210682
Koinuma et al
(n=17)
PMID 16247484
Barrier et al
(n=18)
PMID 16091735
Barrier et al
(n=50)
PMID 16966692

Cox
model

Recurrence

80.00

96.20

88.10

91.66

Multilayer
perceptron

Lymph
node status

71.40

90.00

80.70

82.35

Threshold
selector

Recurrence

88.90

77.80

83.35

83.33

IB1

Recurrence

76.00

80.00

78.00

78.00

NCI 60 U133A
(n=34)

Threshold
selector

94.10

88.20

91.15

91.17

NCI 60 U133B
(n=34)

Threshold
selector

88.23

88.23

88.23

88.23

Drug
response
(5-FU)
Drug
response
(5-FU)
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4.4 Study Design for the 5-gene signature
Colon cancer data from Ried et al (n=73)

Applying t-test on genes having > 5 missing values to determine differential gene
expression in lymph node negative versus positive patients

Selecting genes passing t-test and all other genes
with ≤ 5 missing values

Splitting data into training (n=36) and testing sets (n=37)

Missing value replacement using knn
algorithm on training set (k=20)

Applying random forests using VarSelRF
package using R software

8-gene signature

Using Infogain attribute selection in Weka to rank the
genes and discarding the 3 genes with lowest ranks

5-gene signature

Validation on Ried et al data, plotting Timedependent ROC and Kaplan Meier plots

Building recurrence prediction model and cross validation
on other colon cancer datasets

Figure 4.7 Block diagram of the study for 5-gene signature
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4.4.1 Experimental procedure
Data Source The colon cancer microarray data from Ried et al. (13) contained 22,464 genes and 73
patient samples, all of them treated for primary adenocarcinomas of the colon. Of these 33 tumor samples
were stage II (lymph node negative) and 40 tumor samples were stage III (lymph node positive).
Log Ratio Every spot on the microarray provides two intensity values each of them associated with a
specific channel. Dividing one intensity by the other gives the expression ratio. We used log ratios as they
are lot easier to work with than regular ratios. The log ratio (532/635) was considered for this analysis
which is log (base 2) transformation of the ratio of medians at wavelengths of 532nm and 635 nm.
Data Preprocessing - t test We investigated whether the observed difference between the two groups
(node positive versus negative) represents a real difference in the total study population from which the
sample was drawn, or whether it just occurred by chance (due to sampling variation), by using t-test. The
number of missing values for each gene was found and t-test was done on genes with more than 5 missing
values to evaluate the difference in the proportions of missing values in node positive versus negative
groups. The genes passing the t-test (p < 0.05, two-sided) were included along with all genes having less
than 5 missing values for further processing. A total of 10,220 genes satisfied this condition.
Training dataset The training dataset consisted of the patient samples with recurrence, survival time ≥ 60
months selected based on the clinical data available for the dataset. The expression data of the 10,220
genes and 36 patients, constituted the training set. The remaining patients formed the testing set.
Missing value replacement The training dataset contained missing values. They were replaced using the
EMV

32

package in R software with k=20. This technique estimates the missing values based on the k

nearest neighbors algorithm. This algorithm selects the k nearest rows that do not contain any missing

32

http://cran.r-project.org/web/packages/EMV/index.html
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values to the one containing at least one missing value, based on the Euclidian distance. Then the missing
values are replaced by the average of the neighbors.
Biomarker identification VarSelRF 33 package in R was used in a series of steps on the training dataset
to find the important features. The recurrence status was used as the class variable. In the first step, a
forest with N trees was built and the features were ranked according to the importance of the variables. In
the second step, 20% of the variables that were least important were removed and a new forest was
constructed with K trees. This step was repeated till there were two genes left. In the experiment, a value
of N = 2000 and K =1000 were considered, because a large number of trees in the initial forests is likely
to produce stable importance measures (23). After fitting all forests, the OOB error rates from all the
fitted random forests were examined and a set of 8 genes leading to the smallest error rate were selected.
The InfoGain attribute selection technique was used to drop three least ranked genes (LOC114659-KIAA0563, cDNA DKFZp564O1172, and NET1) and obtained the 5-gene signature. Table 4.25 shows the
5-gene signature.
Table 4.25 The 5-gene signature for predicting colon cancer recurrence.
GENE NAME
TPD52L2-tumor protein D52-like2
CDNA FLJ44020 fis, clone TESTI4026295
ZNF187-zinc finger protein 187 (ZNF187)
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

33

ID
H200013992
H200020685
H200015602
H200018991
H200006643

http://cran.r-project.org/web/packages/varSelRF/index.html

76

4.5 Results
4.5.1 Building prediction model using Weka
The training set consisted of expression data of the 5-gene signature in 36 patients (10 patients having
recurrence within 5 years after surgery and 26 patients having survival time more than 5 years without
recurrence). The remaining patients formed the testing set. 10-fold cross validation was used on the
training dataset. Different classification schemes in Weka were applied on the training set to find the best
scheme. Table 4.26 shows the top five classifiers including Random Tree, KStar, AD Tree, IB1, and
Multilayer perceptron based on their prediction accuracies. Random Tree classifier performed better than
the other classifiers. It had a sensitivity of 70.00%, a specificity of 88.46% and an overall accuracy of
83.33%. Table 4.27 shows the confusion matrix for Random Tree classifier. The difference in overall
accuracy between Random Tree and other classifiers was not statistically significant due to the small
sample size. The Random Tree classifier model was saved and used to predict class (recurrence/no
recurrence) for patients in the testing set. Table 4.28 shows the predicted class for patients in the testing
set using the Random Tree prediction model and compares it with the class predictions obtained from the
Cox model.
Table 4.26 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 5-gene signature. The improved overall accuracy of the prediction with the Random Tree
classifier compared with other methods was assessed by significance testing (N = 36).
Classifier

Sensitivity
(%)

Specificity
(%)

Random Tree
KStar
AD Tree
IB1
Multilayer perceptron

70.00
40.00
50.00
30.00
30.00

88.46
92.30
84.60
88.50
84.60
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(Sensitivity+
Specificity)/2
(%)
79.23
66.15
67.30
59.25
57.30

Overall
Accuracy
(%)
83.33
77.77
75.00
72.22
69.44

P-value

< 0.28
< 0.19
< 0.13
< 0.08

Table 4.27 Confusion matrix obtained from the Random Tree classifier for predicting recurrence
using the 5-gene signature.
Actual/Predicted

a (no recurrence)

b (recurrence)

a (no recurrence)

23

3

b (recurrence)

3

7

78

Table 4.28 Predicting recurrence in patients from the testing dataset using the 5-gene signature.
Serial.
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Patient
Number
CC-P1
CC-P2
CC-P4
CC-P7
CC-P8
CC-P10
CC-P13
CC-P18
CC-P20
CC-P21
CC-P22
CC-P23
CC-P25
CC-P28
CC-P29
CC-P31
CC-P34
CC-P35
CC-P37
CC-P38
CC-P40
CC-P42
CC-P44
CC-P46
CC-P47
CC-P48
CC-P50
CC-P51
CC-P55
CC-P56
CC-P60
CC-P62
CC-P66
CC-P68
CC-P70
CC-P71
CC-P72

Prediction by
Random Tree
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
No recurrence

Prediction by
Cox model
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
Recurrence
No recurrence
Recurrence
No recurrence
No recurrence
Recurrence
Recurrence
No recurrence
Recurrence
Recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
No recurrence
Recurrence
Recurrence
Recurrence
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Match
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
-

4.5.2 Plotting Kaplan-Meier curves based on the patient subgroups obtained from
Random Tree prediction model on data from Ried et al (n=73) using the 5-gene
signature
The Random Tree recurrence prediction model discussed in the previous section generated two subgroups
of patients, recurrence and no recurrence on the training and testing data sets. Kaplan-Meier curves were
plotted based on the expression data of 5-gene signature in the 73 patient samples (Ried et al) and the
patient subgroups obtained from Random Tree prediction model. The Kaplan-Meier plots generated
significant patient stratification into no recurrence and recurrence groups (p < 0.05, n=73, log-rank tests),
with distinct relapse-free survival. Figure 4.8 shows the survival probabilities for each of the patient
subgroups for relapse-free survival.

Figure 4.8 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival using the 5gene signature, based on patient subgroups obtained from Random Tree recurrence prediction
model.

4.5.3 Time-dependent ROC analyses on data from Ried et al (n=73)
To explore whether the 5-gene recurrence signature could predict patient disease-free survival and overall
survival, the survival and status information along with the expression data of the 5 genes were used for
getting the time-dependent ROC curves. The accuracy of 5-year relapse-free survival prediction using
these 5 genes is 0.73 and 5-year overall survival prediction is 0.73, as represented by the AUC.
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Figure 4.9 Time-dependent ROC plots on data from Ried et al (n=73) for relapse-free survival and
overall survival using the 5-gene signature.

4.5.4 Kaplan-Meier analyses on data from Ried et al (n=73)
The Cox model based on the expression of the 5-gene signature was used to get recurrence risk scores for
all 73 patient samples. The choices for choosing a cut-off value for patient stratification are the peak value
from histogram, mean risk score or median risk score. In this analysis, the peak value from histogram was
chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.25 and -0.5 were chosen
for relapse-free survival and overall survival, respectively. The pamr package in R was used to plot the
relapse-free survival probability of low-risk and high-risk groups. The low-risk and high-risk groups had
distinct relapse-free survival (p = 0.01, n=73, log-rank tests). The low-risk and high-risk groups had
distinct overall survival (p = 0.04, n=73, log-rank tests).
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Figure 4.10 Histograms of risk scores obtained from Cox model for relapse-free survival and
overall survival using the 5-gene signature.

Figure 4.11 Kaplan-Meier plots on data from Ried et al (n=73) for relapse-free survival and overall
survival using the 5-gene signature.

Out of the 73 patients in the colon cancer data from Ried et al, 26 patients remained relapse-free for more
than 5 years and 10 patients had recurrence within 5 years after surgery. To test the performance of the 5gene signature the subgroups obtained for the above group of 36 patients from the Cox model were
compared with their actual clinical outcomes. Table 4.29 shows the different parameters obtained from
the Cox model using the 5-gene signature, for relapse-free survival and overall survival, respectively.
Tables 4.30 and 4.31, show the comparison of predicted clinical outcome for patients with their actual
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follow-up information, for relapse-free survival and overall survival, respectively. The Cox model had a
sensitivity of 70.0%, a specificity of 80.8%, and an overall accuracy of 77.8%, for predicting relapse-free
survival. In predicting overall survival, it had a sensitivity of 30.0%, a specificity of 91.7%, and an overall
accuracy of 63.6%.
Table 4.29 Different parameters obtained from Cox model using the 5-gene signature for relapsefree survival and overall survival.

Gene symbol
TPD52L2
CDNAFLJ44020
ZNF187
HSPA14
SLC25A5

Relapse-free survival
exp
se
coef
(coef) (coef)
1.0024 2.725 0.571
0.6445 1.905 0.483
-0.0248 0.975 0.266
0.0749 1.078 0.344
-0.1238 0.884 0.349

pvalue
0.079
0.180
0.930
0.830
0.720

z-score
1.7548
1.3351
-0.0935
0.2181
-0.3547

coef
0.519
0.389
0.081
-0.159
-0.092

Overall survival
exp
se
z(coef) (coef) score
1.680 0.325 1.596
1.476 0.278 1.398
1.084 0.075 1.079
0.853 0.214 -0.742
0.912 0.249 -0.368

pvalue
0.11
0.16
0.28
0.46
0.71

Table 4.30 Comparison of the sub groups predicted from the Cox model using the 5-gene signature
with the actual subgroups for relapse-free survival.
Recurrence
No recurrence

Recurrence
7
5

No recurrence
3
21

Sensitivity (%)

Specificity (%)

Overall Accuracy (%)

70.0

80.8

77.8

Table 4.31 Comparison of the sub groups predicted from the Cox model using the 5-gene signature
with the actual subgroups for overall survival.
Death
Alive

Death
6
2

Alive
14
22

Sensitivity (%)

Specificity (%)

Overall Accuracy (%)

30.0

91.7

63.6

The Cox model was used for stratifying all the 73 patient samples in Ried et al data into low-risk and
high-risk groups based on the 5-gene signature. Out of the 73 patients, a total of 37 patients had no
recurrence with survival times less than 5 years. Twenty-nine patients had overall survival times less than
5 years without any event (death). The relapse outcome for the 37 patients and the overall survival
outcome for the 29 patients is currently unknown. Table 4.32 shows the prospective prognostic
predictions of these patients obtained from the Cox model for relapse-free survival and overall survival,
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respectively. The follow-up information for these patients is being collected. When it becomes available
in the future, the predictions can be compared with it.
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Table 4.32 Patient subgroups obtained from the Cox model for relapse-free survival using the 5gene signature.
Serial
Number

Patient ID

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

CC-P1
CC-P2
CC-P4
CC-P7
CC-P8
CC-P10
CC-P13
CC-P18
CC-P20
CC-P21
CC-P22
CC-P23
CC-P25
CC-P28
CC-P29
CC-P31
CC-P34
CC-P35
CC-P37
CC-P38
CC-P40
CC-P42
CC-P44
CC-P46
CC-P47
CC-P48
CC-P50
CC-P51
CC-P55
CC-P56
CC-P60
CC-P62
CC-P66
CC-P68
CC-P70
CC-P71
CC-P72

Predicted group by
Cox model (RFS)
Low Risk
High Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
High Risk
High Risk
Low Risk
High Risk
Low Risk
Low Risk
High Risk
High Risk
Low Risk
High Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
High Risk
High Risk
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Patient ID
CC-P1
CC-P4
CC-P7
CC-P8
CC-P9
CC-P11
CC-P13
CC-P16
CC-P18
CC-P20
CC-P21
CC-P22
CC-P25
CC-P28
CC-P31
CC-P35
CC-P36
CC-P37
CC-P38
CC-P40
CC-P48
CC-P50
CC-P51
CC-P60
CC-P62
CC-P66
CC-P71
CC-P72
CC-P73

Predicted group by
Cox model (OS)
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
High Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
Low Risk
High Risk
Low Risk
Low Risk

4.5.5 Independence of 5-gene recurrence signature of tumor stage
This part of the study was focused on verifying if the recurrence predictions obtained on Ried et al data
were statistically significant when validated separately in Stage II and Stage III patients. It was seen that
the 5-gene signature could stratify the patients into low-risk and high-risk groups in Stage II and Stage III
samples individually with distinct relapse-free survival. The patient subgroups were obtained based on the
Random Tree model. The patients belonging to the low-risk group had higher survival probabilities than
those belonging to the high-risk group. Based on the predictions from Cox model using the 5-gene
signature, Kaplan-Meier plots were plotted in Stage II and Stage III samples separately. But the patient
stratification was not statistically significant and the results were not reported. So it can be said that
Random Tree model is the best model for predicting recurrence using the 5-gene signature. These results
confirm that the 5-gene recurrence signature might be applicable to prognostic categorization for the
clinical management of colon cancer.

Figure 4.12 The 5-gene signature stratifies patients in Stage II tumors and Stage III tumors into
distinct low-risk and high-risk groups for relapse-free survival using the random tree model.
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4.5.6 External validation of the 5-gene signature on other colon cancer data
This part of the study sought to explore the extent to which the 5-gene signature could be used for
prediction of lymph node status, recurrence, and drug response in publicly available independent datasets.
More than 50 classifiers available in Weka software were tested using a leave-one-out cross validation
technique on each of the independent datasets to find a suitable classification scheme for validation. Due
to the different number of attributes (matching genes), sample sizes and prediction variables one specific
scheme could not be used for validation on all the datasets. Different classifiers had to be employed on
the validation datasets to get fair prediction accuracy. As far as possible the same set of classifiers were
presented in the comparison tables of validation datasets to provide a fair evaluation of the performance.
The exact same set of classifiers could not be compared over all the validation datasets due to poor
performances of classifiers on some datasets and good performances on other datasets. The following
sections discuss the validation results and comparisons of various classifiers on the independent datasets
in detail.

4.5.6.1 Predicting lymph node status by leave-one-out cross validation on data from
Koinuma et al. (n=17) PMID 16247484
The data from Koinuma et al (Affymetrix HG U133 B platform) consisted of 20 patient samples of which
3 patients were Duke’s stage D. The Duke’s stage D patients were not considered for validation. The
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 2
matching genes (Table 4.33). The data used for validation consisted of the expression of these 2 genes in
the 17 patient samples. Weka software was used for validation and lymph node status (positive/negative)
was predicted. Different classification schemes including KStar, Random Tree, Threshold selector,
Multilayer perceptron, and AD Tree were applied to this dataset to find the best scheme. Table 4.34
shows the comparison between KStar and some of the classifiers used for validation on other datasets.
KStar classifier performed better than the other classifiers. It had a sensitivity of 57.10%, a specificity of
70.00%, and an overall accuracy of 64.70%. Table 4.35 shows the confusion matrix for KStar classifier.
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The difference in overall accuracy between KStar and other classifiers was not statistically significant due
to the small sample size.
Table 4.33 Matching genes in Koinuma et al data.
GENE NAME
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

ID
H200018991
H200006643

Table 4.34 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 5-gene signature. The improved overall accuracy of the prediction with the KStar
classifier compared with other methods was assessed by significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

KStar
Random Tree
Threshold selector
Multilayer perceptron
AD Tree

57.10
57.10
85.70
28.60
28.60

70.00
60.00
40.00
50.00
50.00

(Sensitivity+
Specificity)/2
(%)
63.55
58.55
62.85
39.30
39.30

Overall
Accuracy
(%)
64.70
58.82
58.82
41.17
41.17

P-value

< 0.37
< 0.37
< 0.09
< 0.09

Table 4.35 Confusion matrix obtained from the KStar classifier for predicting lymph node status
using the 5-gene signature.
Actual/Predicted
a (positive)
b (negative)

a (positive)
4
3

b (negative)
3
7

4.5.6.2 Predicting recurrence by leave-one-out cross validation on data from Barrier et al.
(n=18) PMID 16091735
The data from Barrier et al (PMID 16091735) consisted of 22,283 genes and 18 patient samples. The
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 4
matching genes (Table 4.36). The data used for validation consisted of the expression of these 4 genes in
the 18 patients. Weka software was used for validation and recurrence (yes/no) was predicted. Different
classification schemes including AD Tree, Random Tree, Threshold selector, KStar, and Multilayer
perceptron were applied to this dataset to find the best scheme. Table 4.37 shows the comparison between
AD Tree and some of the classifiers used for validation on other datasets. AD Tree classifier performed
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better than the other classifiers. It had a sensitivity of 88.88%, a specificity of 88.88%, and an overall
accuracy of 88.88%. Table 4.38 shows the confusion matrix for AD Tree classifier. The difference in
overall accuracy between AD Tree and other classifiers was not statistically significant due to the small
sample size.
Table 4.36 Matching genes in Barrier et al data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187 (ZNF187)
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

ID
H200013992
H200015602
H200018991
H200006643

Table 4.37 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 5-gene signature. The improved overall accuracy of the prediction with the AD Tree
classifier compared with other methods was assessed by significance testing (N = 18).
Classifier

Sensitivity
(%)

Specificity
(%)

AD Tree
Random Tree
Threshold selector
KStar
Multilayer perceptron

88.88
66.66
77.80
77.80
77.80

88.88
66.66
66.70
55.60
77.80

(Sensitivity+
Specificity)/2
(%)
88.88
66.66
72.25
66.70
77.80

Overall
Accuracy
(%)
88.88
66.66
72.22
66.66
77.77

P-value

< 0.06
< 0.10
< 0.06
< 0.18

Table 4.38 Confusion matrix obtained from the AD Tree classifier for predicting recurrence using
the 5-gene signature.
Actual/Predicted
a (recurrence)
b (no recurrence)

a (recurrence)
8
1

b (no recurrence)
1
8

4.5.6.3 Predicting recurrence by leave-one-out cross validation on data from Barrier et al.
(n=50) (PMID 16966692)
The data from Barrier et al (PMID 16966692) consisted of 22,283 genes and 50 patient samples. The
search for matching genes with the 5-gene signature was done using the Affymetrix ids. There were 4
matching genes (Table 4.39). The data used for validation consisted of the expression of these 4 genes in
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the 50 patient samples. Weka software was used for validation and recurrence (yes/no) was predicted.
Different classification schemes including Threshold selector, KStar, IB1, AD Tree, and Multilayer
perceptron were applied to this dataset to find the best scheme. Table 4.40 shows the comparison between
Threshold selector and some of the classifiers used for validation on other datasets. Threshold selector
classifier performed better than the other classifiers. It had a sensitivity of 84.00%, a specificity of
68.00%, and an overall accuracy of 76.00%. Table 4.41 shows the confusion matrix for Threshold
selector classifier. The difference in overall accuracy between Threshold selector and other classifiers was
not statistically significant due to the small sample size.
Table 4.39 Matching genes in Barrier et al data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187 (ZNF187)
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

ID
H200013992
H200015602
H200018991
H200006643

Table 4.40 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 5-gene signature. The improved overall accuracy of the prediction with the Threshold
selector classifier compared with other methods was assessed by significance testing (N = 50).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
KStar
IB1
AD Tree
Multilayer perceptron

84.00
80.00
76.00
76.00
60.00

68.00
68.00
72.00
64.00
68.00

(Sensitivity+
Specificity)/2
(%)
76.00
74.00
74.00
70.00
64.00

Overall
Accuracy
(%)
76.00
74.00
74.00
70.00
64.00

Table 4.41 Confusion matrix obtained from the Threshold selector classifier for predicting
recurrence using the 5-gene signature.
Actual/Predicted
a (no recurrence)
b (recurrence)

a (no recurrence)
17
4

b (recurrence)
8
21
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P-value

< 0.40
< 0.40
< 0.24
< 0.09

4.5.6.4 Predicting recurrence by leave-one-out cross validation on data from Barrier et al.
(n=24) (PMID 17043639)
The data from Barrier et al (PMID 17043639) consisted of 22,283 genes and 24 patient samples. The
search for matching genes was done using the Affymetrix ids. There were 4 matching genes (Table 4.42).
The data used for validation consisted of the expression of these 4 genes in the 24 patient samples. Weka
software was used for validation and recurrence (yes/no) was predicted. Different classification schemes
including Threshold selector, Logistic regression, LWL, Multilayer perceptron, and AD Tree were
applied to this dataset to find the best scheme. Table 4.43 shows the comparison between Threshold
selector and some of the classifiers used for validation on other datasets. Threshold selector classifier
performed better than the other classifiers. It had a sensitivity of 50.00%, a specificity of 92.90%, and an
overall accuracy of 75.00%. Table 4.44 shows the confusion matrix for Threshold selector classifier. The
difference in overall accuracy between Threshold selector and other classifiers was not statistically
significant due to the small sample size.
Table 4.42 Matching genes in Barrier et al data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187 (ZNF187)
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

ID
H200013992
H200015602
H200018991
H200006643

Table 4.43 Comparison of accuracies obtained from different classifiers for predicting recurrence
using the 5-gene signature. The improved overall accuracy of the prediction with the Threshold
selector classifier compared with other methods was assessed by significance testing (N = 24).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
Logistic regression
LWL
Multilayer perceptron
AD Tree

50.00
60.00
70.00
60.00
70.00

92.90
78.60
71.40
78.60
64.30

(Sensitivity+
Specificity)/2
(%)
47.63
69.30
70.70
69.30
67.15
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Overall
Accuracy
(%)
75.00
70.83
70.83
70.83
66.66

P-value

< 0.38
< 0.38
< 0.38
< 0.27

Table 4.44 Confusion matrix obtained from the Threshold selector classifier for predicting
recurrence using the 5-gene signature.
Actual/Predicted
a (no recurrence)
b (recurrence)

a (no recurrence)
13
5

b (recurrence)
1
5

4.5.6.5 Predicting the response of cell lines in NCI-60 (U133A GCRMA) data (n=34) by
leave-one-out cross validation
This dataset 34 consisted of 21,225 genes and 60 cell lines (41). Our focus was on the sensitive and
resistant cell lines, so cell lines with intermediate response were not considered for validation. A total of
34 cell lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search
for matching genes was done using the gene symbols. There were 4 matching genes (Table 4.45). The
data used for validation consisted of the expression of these 4 genes in the 34 cell lines. Weka software
was used for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was
predicted. Different classification schemes including Threshold selector, Multilayer perceptron, Random
Tree, KStar, and AD Tree were applied to this dataset to find the best scheme. Table 4.46 shows the
comparison between Threshold selector and some of the classifiers used for validation on other datasets.
Threshold selector classifier performed better than the other classifiers. It had a sensitivity of 82.40%, a
specificity of 64.70%, and an overall accuracy of 73.52%. Table 4.47 shows the confusion matrix for
Threshold selector classifier. The difference in overall accuracy between Threshold selector and
Multilayer perceptron (p < 0.01), KStar (p < 0.04), AD Tree (p < 0.02) was statistically significant.
Table 4.45 Matching genes in NCI-60 U133A data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187 (ZNF187)
HSPA14-heat shock 70kDa protein 14
SLC25A5-solute carrier family 25

34

ID
H200013992
H200015602
H200018991
H200006643

http://discover.nci.nih.gov/cellminer/loadDownload.do
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Table 4.46 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 5-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
Multilayer perceptron
Random Tree
KStar
AD Tree

82.40
52.90
58.80
64.70
41.20

64.70
35.30
52.90
41.20
52.90

(Sensitivity+
Specificity)/2
(%)
73.55
44.10
55.85
52.95
47.05

Overall
Accuracy
(%)
73.52
44.11
55.88
52.94
47.05

P-value

< 0.01
< 0.07
< 0.04
< 0.02

Table 4.47 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 5-gene signature.
Actual/Predicted

a (sensitive)

b (resistant)

a (sensitive)

14

3

b (resistant)

6

11

4.5.6.6 Predicting the response of cell lines in NCI-60 (U133B GCRMA) data (n=34) by
leave-one-out cross validation
This dataset 35 consisted of 17910 genes and 60 cell lines (41). Our focus was on the sensitive and resistant
cell lines, so cell lines with intermediate response were not considered for validation. A total of 34 cell
lines (17 sensitive and the other 17 resistant to the drug 5-FU) were used in validation. The search for
matching genes was done using the gene symbols. There was 1 matching gene (Table 4.48). The data
used for validation consisted of the expression of this gene in the 34 cell lines. Weka software was used
for validation and the response (sensitive/resistant) for the drug 5-FU (fluorouracil) was predicted.
Different classification schemes including Threshold selector, AD Tree, Random Tree, IB1, and KStar
were applied to this dataset to find the best scheme. Table 4.49 shows the comparison between Threshold
selector and some of the classifiers used for validation on other datasets. Threshold selector classifier
performed better than the other classifiers. It had a sensitivity of 82.35%, a specificity of 82.35%, and an

35
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overall accuracy of 82.35%. Table 4.50 shows the confusion matrix for Threshold selector classifier. The
difference in overall accuracy between Threshold selector and AD Tree (p < 0.05), Random Tree (p <
0.01), IB1 (p < 0.05), KStar (p < 0.01) was statistically significant.
Table 4.48 Matching genes in NCI-60 U133B data.
GENE NAME
HSPA14-heat shock 70kDa protein 14

ID
H200018991

Table 4.49 Comparison of accuracies obtained from different classifiers for predicting drug
response using the 5-gene signature. The improved overall accuracy of the prediction with the
Threshold selector classifier compared with other methods was assessed by significance testing (N =
34).
Classifier

Sensitivity
(%)

Specificity
(%)

Threshold selector
AD Tree
Random Tree
IB1
KStar

82.35
64.70
52.90
52.90
58.80

82.35
64.70
58.80
47.10
29.40

(Sensitivity+
Specificity)/2
(%)
82.35
64.70
55.85
50.00
44.10

Overall
Accuracy
(%)
82.35
64.70
55.88
50.00
44.11

P-value

< 0.05
< 0.01
< 0.01
< 0.01

Table 4.50 Confusion matrix obtained from the Threshold selector classifier for predicting drug
response using the 5-gene signature.
Actual/Predicted

a (sensitive)

b (resistant)

a (sensitive)

14

3

b (resistant)

3

14
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4.5.7 Summary of validation results of 5-gene signature
Table 4.51 shows the details of different validation datasets, predicted variables, classifiers used and
different accuracies obtained using the 5-gene signature. For each dataset the classifier with the highest
overall accuracy was reported.
Table 4.51 Summary of validation results of 3-gene signature on Ried et al data, independent colon
cancer datasets and NCI 60 data.
Dataset
Ried et al training set
(n=36)
PMID 17210682
Ried et al training set
(n=36)
PMID 17210682
Koinuma et al
(n=17)
PMID 16247484
Barrier et al
(n=18)
PMID 16091735
Barrier et al
(n=50)
PMID 16966692
Barrier et al
(n=24)
PMID 17043639

Classifier

Predicted
variable

Sensitivity
(%)

Specificity
(%)

(Sensitivity +
Specificity)/2
(%)

Overall
accuracy
(%)

Random
Tree

Recurrence

70.00

88.46

79.23

83.33

Cox
model

Recurrence

70.00

80.80

75.40

77.80

KStar

Lymph
node status

57.10

70.00

63.55

64.70

AD Tree

Recurrence

88.88

88.88

88.88

88.88

Threshold
selector

Recurrence

84.00

68.00

76.00

76.00

Threshold
selector

Recurrence

50.00

92.90

47.63

75.00

82.40

64.70

73.55

73.52

82.35

82.35

82.35

82.35

NCI 60 U133A
(n=34)

Threshold
selector

NCI 60 U133B
(n=34)

Threshold
selector

Drug
response
(5-FU)
Drug
response
(5-FU)
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4.6 Comparison of 3-gene and 5-gene signatures
This part of the study discusses the 3-gene and 5-gene recurrence signatures and compares them. The
gene SLC25A5 was common in both the gene signatures. Based on the prediction accuracies obtained
from the independent validation datasets, it can be seen that the 3-gene signature performs better than the
5-gene signature. But the patient stratification in Stage II and Stage II tumor samples, by both the gene
signatures were statistically significant. It can be concluded that both the 3-gene and 5-gene signatures
could be used to predict recurrence and identify patients at high-risk of recurrence. Table 4.52 shows the
comparison between 3-gene signature and 5-gene signature in detail. The difference in the prediction
accuracies obtained from 3-gene and 5-gene signature on NCI-60 U133A data was statistically
significant, whereas the results on other datasets were not significant.
Table 4.52 Comparison of prediction accuracies obtained from 3-gene and 5-gene signatures on
independent datasets. The improved overall accuracy of the prediction with the 3-gene signature
compared with the 5-gene signature was assessed by significance testing.

Dataset

Ried et al
training
dataset
(n=36)

Ried et al
training
dataset
(n=36)

Predicted
variable

Recurrence

Recurrence

LWL

Cox model

80.00

80.00

96.20

3-gene signature

Classifier
Sensitivity
(%)
Specificity
(%)
Overall
accuracy
(%)

5-gene signature

Classifier
Sensitivity
(%)
Specificity
(%)
Overall
accuracy
(%)
P-value

NCI-60
U133A
data
(n=34)
Drug
response
Threshold
selector

NCI-60
U133B
data
(n=34)
Drug
response
Threshold
selector

76.00

94.10

88.23

77.80

80.00

88.20

88.23

82.35

83.33

78.00

91.17

88.23

Cox model

KStar

AD Tree

Threshold
selector

Threshold
selector

Threshold
selector

70.00

70.00

57.10

88.88

84.00

82.40

82.35

88.46

80.80

70.00

88.88

68.00

64.70

82.35

83.33

77.80

64.70

88.88

76.00

73.52

82.35

< 0.15

< 0.06

< 0.13

< 0.31

< 0.41

< 0.03

< 0.25

Koinuma
et al data
(n=17)

Barrier
et al data
(n=18)

Barrier
et al data
(n=50)

Recurrence

Recurrence

Threshold
selector

IB1

71.40

88.90

96.10

90.00

91.66

91.70

Random
Tree

Lymph
node status
Multilayer
perceptron
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4.7 Summary
In this chapter, we described how the recurrence gene signatures were identified. A combinatorial scheme
was utilized for feature selection. Firstly, variable selection using random forests was applied on the
preprocessed data to identify gene subsets, and secondly, InfoGain attribute selection technique was
applied to reduce the dimensionality of the gene signatures without decreasing the predictive power. Two
prediction models were built independently with the 3-gene and the 5-gene signatures using classifiers in
Weka software to predict the risk stage of the patients in the testing set (patients whose recurrence status
is currently unknown). The subgroups of patients without recurrence and survival time more than 5 years,
and the patients having recurrence within 5 years after surgery obtained from the Cox model had a
sensitivity of 80.0% and a specificity of 96.1%, using the 3-gene signature. Using the 5-gene signature,
the sensitivity was 70.0% and the specificity was 80.8%. The Kaplan-Meier plots for the 3-gene signature
and the 5-gene signature on Ried et al data obtained based on the Cox model stratified patients into
distinct low-risk and high-risk groups. Both the gene signatures were cross validated on independent
colon cancer data sets. The drug response of 5-FU (fluorouracil) on the NCI-60 cell line data was
predicted. To confirm the prognostic applicability of the recurrence gene signatures, Kaplan Meier curves
were plotted separately for Stage II and Stage III patients based on the predicted subgroups. The
stratification was statistically significant (log-rank tests, p<0.05) for the 3-gene and 5-gene signatures.
This confirms that it is feasible to predict recurrence in the Stage II and Stage III tumors with the 3-gene
and 5-gene signatures.
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Chapter 5
Validation of the identified gene signatures on rectal cancer data
5.1 Introduction
As colon cancer and rectal cancer are anatomically related, this part of the study sought to explore
whether the identified colon cancer gene signatures could predict lymph node metastasis and generate
significant patient stratification into low-risk and high-risk groups on rectal cancer data. The rectal cancer
data was obtained from Ried et al (n=29) (PMID 16397240) (32). The 29 patients included in this study
were all participants in a multicenter, randomized prospective phase III clinical trial treated at the
Department of General Surgery, University Medical Center Gottingen, Germany. This data set of 29
carcinomas and 20 mucosa biopsies includes 12 patient-matched pairs of biopsies from tumor and normal
mucosa. The lymph node status, chemoradiotherapy response, disease-free survival, and overall survival
information was available for all the patients. All the patients received a dose of 50.4Gy of radiation
accompanied by FU (Fluorouracil). The following sections describe the validation results of the 9-gene
lymph node status signature, 3-gene and 5-gene recurrence signatures on rectal cancer data including
time-dependent ROC and Kaplan-Meier analyses.

5.2 Validation results of the 9-gene signature on rectal cancer data
5.2.1 Predicting lymph node status by leave-one-out cross validation on cDNA 1 files
The cDNA 1 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.1). The data
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software
was used for validation and lymph node status (negative/positive) was predicted. Different classification
schemes including AdaboostM1, Multiboost AB, Random Tree, IB1, and Multilayer perceptron were
applied to this dataset to find the best scheme. Table 5.2 shows the comparison between AdaboostM1 and
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some of the classifiers used for validation on other datasets. AdaboostM1 classifier performed better than
the other classifiers. It had a sensitivity of 87.50%, a specificity of 57.10%, and an overall accuracy of
78.26%. Table 5.3 shows the confusion matrix for AdaboostM1 classifier. The difference in overall
accuracy between AdaboostM1 and other classifiers was not statistically significant.
Table 5.1 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
PLXNB2-plexin B2, mRNA
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200000861
H200021334

Table 5.2 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the
AdaboostM1 classifier compared with other methods was assessed by significance testing (N = 23).
Classifier

Sensitivity
(%)

Specificity
(%)

AdaboostM1
Multiboost AB
Random Tree
IB1
Multilayer perceptron

87.50
81.30
81.30
87.50
81.30

57.10
28.60
28.60
42.90
28.60

(Sensitivity
+Specificity)/2
(%)
72.30
54.95
54.95
65.20
54.95

Overall
Accuracy
(%)
78.26
65.21
65.21
73.91
65.21

P-value

<0.17
<0.17
<0.35
<0.17

Table 5.3 Confusion matrix obtained from the AdaboostM1 classifier for predicting lymph node
status using the 9-gene signature.
Actual/Predicted
a (node negative)
b (node positive)

a (node negative)
4
2

b (node positive)
3
14

5.2.2 Predicting lymph node status by leave-one-out cross validation on cDNA2 files
The cDNA 2 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.4). The data
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software
was used for validation and lymph node status (negative/positive) was predicted. Different classification
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schemes including AdaboostM1, Multiboost AB, Random Tree, IB1, and JRip were applied to this dataset
to find the best scheme. Table 5.5 shows the comparison between AdaboostM1 and some of the classifiers
used for validation on other datasets. AdaboostM1 classifier performed better than the other classifiers. It
had a sensitivity of 93.80%, a specificity of 42.90%, and an overall accuracy of 78.26%. Table 5.6 shows
the confusion matrix for AdaboostM1 classifier. The difference in overall accuracy between AdaboostM1
and other classifiers was not statistically significant due to the small sample size.
Table 5.4 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
PLXNB2-plexin B2, mRNA
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200000861
H200021334

Table 5.5 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the
AdaboostM1 classifier compared with other methods was assessed by significance testing (N = 23).
Classifier

Sensitivity
(%)

Specificity
(%)

AdaboostM1
Multiboost AB
Random Tree
IB1
JRip

93.80
75.00
68.80
68.80
93.80

42.90
14.30
28.60
42.90
28.60

(Sensitivity+
Specificity)/2
(%)
68.35
44.65
48.70
55.85
61.20

Overall
Accuracy
(%)
78.26
56.52
56.52
60.86
73.91

P-value

<0.06
<0.06
<0.11
<0.37

Table 5.6 Confusion matrix obtained from the AdaboostM1 classifier for predicting lymph node
status using the 9-gene signature.
Actual/Predicted

a (node negative)

b (node positive)

a (node negative)

3

4

b (node positive)

1

15

5.2.3 Predicting lymph node status by leave-one-out cross validation on tumor
biopsies 1 files
The tumor biopsies 1 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.7).
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The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka
software was used for validation and lymph node status (negative/positive) was predicted. Different
classification schemes including Decision stump, Multilayer perceptron, Random Tree, AdaboostM1, and
IB1 were applied to this dataset to find the best scheme. Table 5.8 shows the comparison between
Decision stump and some of the classifiers used for validation on other datasets. Decision stump classifier
performed better than the other classifiers. It had a sensitivity of 75.00%, a specificity of 80.00%, and an
overall accuracy of 76.47%. Table 5.9 shows the confusion matrix for Decision stump classifier. The
difference in overall accuracy between Decision stump and Multilayer perceptron (p < 0.04), Random
Tree (p < 0.04) was statistically significant.
Table 5.7 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
DC50-hypothetical protein DC50
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200019106
H200016227
H200020589
H200004174
H200015474
H200021334

Table 5.8 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the
Decision stump classifier compared with other methods was assessed by significance testing (N =
17).
Classifier

Sensitivity
(%)

Specificity
(%)

Decision stump
Multilayer perceptron
Random Tree
AdaboostM1
IB1

75.00
58.30
58.30
66.70
58.30

80.00
20.00
20.00
20.00
40.00
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(Sensitivity+
Specificity)/2
(%)
77.50
39.15
39.15
43.33
49.15

Overall
Accuracy
(%)
76.47
47.05
47.05
52.94
52.94

P-value

<0.04
<0.04
<0.08
<0.08

Table 5.9 Confusion matrix obtained from the Decision stump classifier for predicting lymph node
status using the 9-gene signature.
Actual/Predicted
a (node positive)
b (node negative)

a (node positive)
9
1

b (node negative)
3
4

5.2.4 Predicting lymph node status by leave-one-out cross validation on tumor
biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.10).
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka
software was used for validation and lymph node status (negative/positive) was predicted. Different
classification schemes including J48, Random Tree, Adaboost M1, Multiboost AB, and Multilayer
perceptron were applied to this dataset to find the best scheme. Table 5.11 shows the comparison between
J48 and some of the classifiers used for validation on other datasets. J48 classifier performed better than
the other classifiers. It had a sensitivity of 75.00%, a specificity of 60.00%, and an overall accuracy of
70.58%. Table 5.12 shows the confusion matrix for J48 classifier. The difference in overall accuracy
between J48 and other classifiers was not statistically significant due to the small sample size.
Table 5.10 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
DC50-hypothetical protein DC50
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200019106
H200016227
H200020589
H200004174
H200015474
H200021334
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Table 5.11 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 9-gene signature. The improved overall accuracy of the prediction with the J48
classifier compared with other methods was assessed by significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

J48
Random Tree
Adaboost M1
Multiboost AB
Multilayer perceptron

75.00
75.00
66.70
75.00
66.70

60.00
40.00
40.00
20.00
40.00

(Sensitivity+
Specificity)/2
(%)
67.50
57.50
53.35
47.50
53.35

Overall
Accuracy
(%)
70.58
64.70
58.82
58.82
58.82

P-value

<0.36
<0.24
<0.24
<0.24

Table 5.12 Confusion matrix obtained from the J48 classifier for predicting lymph node status
using the 9-gene signature.
Actual/Predicted

a (node positive)

b (node negative)

a (node positive)

9

3

b (node negative)

2

3

5.2.5 Predicting chemoradiotherapy response by leave-one-out cross validation on
cDNA 1 files
The cDNA 1 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.13). The data
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software
was used for validation and chemoradiotherapy response (yes/no) was predicted. Different classification
schemes including JRip, J48, AdaboostM1, Random Tree, and Multilayer perceptron were applied to this
dataset to find the best scheme. Table 5.14 shows the comparison between JRip and some of the
classifiers used for validation on other datasets. JRip classifier performed better than the other classifiers.
It had a sensitivity of 55.60%, a specificity of 85.70%, and an overall accuracy of 73.91%. Table 5.15
shows the confusion matrix for JRip classifier. The difference in overall accuracy between JRip and J48
(p < 0.04) was statistically significant.
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Table 5.13 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
PLXNB2-plexin B2, mRNA
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200000861
H200021334

Table 5.14 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the
prediction with the JRip classifier compared with other methods was assessed by significance
testing (N = 23).
Classifier

Sensitivity
(%)

Specificity
(%)

JRip
J48
AdaboostM1
Random Tree
Multilayer perceptron

55.60
33.30
44.40
44.40
55.60

85.70
57.10
78.60
71.40
64.30

(Sensitivity+
Specificity)/2
(%)
70.65
45.20
61.50
57.90
59.95

Overall
Accuracy
(%)
73.91
47.82
65.21
60.86
60.86

P-value

<0.04
<0.27
<0.18
<0.18

Table 5.15 Confusion matrix obtained from the JRip classifier for predicting response using the 9gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
5
2

b (no response)
4
12

5.2.6 Predicting chemoradiotherapy response by leave-one-out cross validation on
cDNA2 files
The cDNA 2 data files from Ried et al (PMID 16397240) consisted of 23 patient samples. The search for
matching genes was done using the gene symbols. There were 3 matching genes (Table 5.16). The data
used for validation consisted of the expression of these 3 genes in the 23 patient samples. Weka software
was used for validation and chemoradiotherapy response (yes/no) was predicted. Different classification
schemes including JRip, AdaboostM1, IB1, AD Tree, and Multiboost AB were applied to this dataset to
find the best scheme. Table 5.17 shows the comparison between JRip and some of the classifiers used for
validation on other datasets. JRip classifier performed better than the other classifiers. It had a sensitivity
of 77.80%, a specificity of 85.70%, and an overall accuracy of 82.60%. Table 5.18 shows the confusion
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matrix for JRip classifier. The difference in overall accuracy between JRip and other classifiers was not
statistically significant due to the small sample size.
Table 5.16 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
PLXNB2-plexin B2, mRNA
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200000861
H200021334

Table 5.17 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the
prediction with the JRip classifier compared with other methods was assessed by significance
testing (N = 23).
Classifier

Sensitivity
(%)

Specificity
(%)

JRip
AdaboostM1
IB1
AD Tree
Multiboost AB

77.80
66.70
44.40
55.60
55.60

85.70
78.60
71.40
78.60
71.40

(Sensitivity+
Specificity)/2
(%)
81.75
72.65
57.90
67.10
63.50

Overall
Accuracy
(%)
82.60
73.91
60.86
69.56
65.21

P-value

<0.24
<0.06
<0.15
<0.10

Table 5.18 Confusion matrix obtained from the JRip classifier for predicting response using the 9gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
7
2

b (no response)
2
12

5.2.7 Predicting chemoradiotherapy response by leave-one-out cross validation on
tumor biopsies 1 files
The tumor biopsies 1 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.19).
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different
classification schemes including Random committee, Multiboost AB, IB1, Multilayer perceptron, and
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KStar were applied to this dataset to find the best scheme. Table 5.20 shows the comparison between
Random committee and some of the classifiers used for validation on other datasets. Random committee
classifier performed better than the other classifiers. It had a sensitivity of 90.00%, a specificity of
28.60%, and an overall accuracy of 64.70%. Table 5.21 shows the confusion matrix for Random
committee classifier. The difference in overall accuracy between Random committee and other classifiers
was not statistically significant due to the small sample size.
Table 5.19 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
DC50-hypothetical protein DC50
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200019106
H200016227
H200020589
H200004174
H200015474
H200021334

Table 5.20 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the
prediction with the Random committee classifier compared with other methods was assessed by
significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

Random committee
Multiboost AB
IB1
Multilayer perceptron
KStar

90.00
80.00
70.00
50.00
70.00

28.60
14.30
42.90
28.60
42.90

(Sensitivity+
Specificity)/2
(%)
59.30
47.15
56.45
39.30
56.45

Overall
Accuracy
(%)
64.70
52.94
58.82
41.17
58.82

Table 5.21 Confusion matrix obtained from the Random committee classifier for predicting
response using the 9-gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
9
5

b (no response)
1
2
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P-value

<0.25
<0.37
<0.09
<0.37

5.2.8 Predicting chemoradiotherapy response by leave-one-out cross validation on
tumor biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 9 matching genes (Table 5.22).
The data used for validation consisted of the expression of these 9 genes in the 17 patient samples. Weka
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different
classification schemes including Logistic regression, IB1, AdaboostM1, Multilayer perceptron, and
Threshold selector were applied to this dataset to find the best scheme. Table 5.23 shows the comparison
between Logistic regression and some of the classifiers used for validation on other datasets. Logistic
regression classifier performed better than the other classifiers. It had a sensitivity of 80.00%, a specificity
of 71.40%, and an overall accuracy of 76.47%. Table 5.24 shows the confusion matrix for Logistic
regression classifier. The difference in overall accuracy between Logistic regression and AdaboostM1 (p
< 0.04) was statistically significant.
Table 5.22 Matching genes in Ried et al rectal cancer data.
GENE NAME
SNRPD3-small nuclear ribonucleoprotein
IFRG28-28kD interferon responsive pro
PLXNB2-plexin B2, mRNA
DC50-hypothetical protein DC50
FLJ11078-hypothetical protein FLJ1107
MGC16044-hypothetical protein MGC1604
RNF6-ring finger protein (C3H2C3 type)
POU6F2-POU domain, class 6,transcript
ITGB1-integrin,beta1 (fibronectin)

ID
H200000411
H200004627
H200000861
H200019106
H200016227
H200020589
H200004174
H200015474
H200021334
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Table 5.23 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 9-gene signature. The improved overall accuracy of the
prediction with the Logistic regression classifier compared with other methods was assessed by
significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

Logistic regression
IB1
AdaboostM1
Multilayer perceptron
Threshold selector

80.00
80.00
60.00
70.00
40.00

71.40
42.90
28.60
57.10
85.70

(Sensitivity+
Specificity)/2
(%)
75.70
61.45
44.30
63.55
62.85

Overall
Accuracy
(%)
76.47
64.70
47.05
64.70
58.82

P-value

<0.23
<0.04
<0.23
<0.13

Table 5.24 Confusion matrix obtained from the Logistic regression classifier for predicting
response using the 9-gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
8
2

b (no response)
2
5

5.2.9 Time-dependent ROC analyses on rectal cancer data from Ried et al (n=23)
using the 9-gene lymph node status signature
To explore whether the 9-gene lymph node status signature could predict patient disease-free survival and
overall survival, the survival and status information along with the expression data of the matching genes
are used for getting the time-dependent ROC curves. There were 3 matching genes with the 9-gene
signature. The expression data of these 3 genes in the 23 patient samples along with the survival
information was used to plot the time-dependent ROC curves. The accuracy of 5-year disease-free
survival prediction is 0.72 and 5-year overall survival prediction is 0.76, as represented by AUC for
cDNA 1 data files. The accuracy of 5-year disease-free survival prediction is 0.79 and 5-year overall
survival prediction is 0.75, as represented by AUC for cDNA 2 data files.
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Figure 5.1 Time-dependent ROC plots on rectal cancer data (n=23) for disease-free survival and
overall survival using the 9-gene signature in cDNA1 data files.

Figure 5.2 Time-dependent ROC plots on rectal cancer data (n=23) for disease-free survival and
overall survival using the 9-gene signature in cDNA 2 data files.
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5.2.10 Kaplan-Meier analyses on Ried et al rectal cancer data (n=23) using the 9gene lymph node status signature
The cDNA 1 files in rectal cancer data were checked for matching genes with the 9-gene signature. There
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.41
and 0.09 were chosen for relapse-free survival and overall survival in cDNA 1 files, respectively. The
pamr package in R was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had
distinct relapse-free survival (p = 0.014, n=23, log-rank tests) and distinct overall survival (p = 0.043,
n=23, log-rank tests), respectively for the data in cDNA1 files. Table 5.25 shows the different parameters
obtained from the Cox model using the 9-gene signature for disease-free survival and overall survival in
cDNA 1 data files.
Table 5.25 Different parameters obtained from Cox model using the 9-gene signature for diseasefree survival and overall survival in cDNA 1 data files.
Gene
Symbol
SNRPD3
PLXNB2
ITGB1

Disease-free survival
exp
se
coef
(coef)
(coef)
-0.541
0.582
0.548
1.955
7.070
1.363
0.009
1.010
0.758

zscore
-0.987
1.435
0.013

pvalue
0.32
0.15
0.99
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Coef
0.476
1.335
0.217

Overall survival
exp
se
z(coef) (coef) score
1.61
0.84 0.567
3.80
1.91 0.699
1.24
1.32 0.164

pvalue
0.57
0.48
0.87

Figure 5.3 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall
survival using the 9-gene signature in cDNA 1 files.

The cDNA 2 files in rectal cancer data were checked for matching genes with the 9-gene signature. There
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values 0.27 and
-0.48 were chosen for relapse-free survival and overall survival in cDNA 2 files, respectively. The pamr
package in R was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had distinct
relapse-free survival (p = 0.041, n=23, log-rank tests) and distinct overall survival (p = 0.0436, n=23,
log-rank tests), respectively for the data in cDNA 2 files. Table 5.26 shows the different parameters
obtained from the Cox model using the 9-gene signature for disease-free survival and overall survival in
cDNA 2 data files.
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Table 5.26 Different parameters obtained from Cox model using the 9-gene signature for diseasefree survival and overall survival in cDNA 2 files.
Gene
Symbol
SNRPD3
PLXNB2
ITGB1

Disease-free survival
exp
se
coef
(coef)
(coef)
-0.122
0.885
0.671
1.262
3.531
1.247
-0.823
0.439
0.882

zscore
-0.182
1.012
-0.933

pvalue
0.86
0.31
0.35

coef
0.876
-0.973
-1.844

Overall survival
exp
se
z(coef) (coef) score
2.401
0.89 0.984
0.378
2.11 -0.461
0.158
1.67 -1.104

pvalue
0.32
0.65
0.27

Figure 5.4 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall
survival using the 9-gene signature in cDNA 2 data files.

5.2.11 Summary of validation results of 9-gene signature on rectal cancer data
Table 5.27 shows the details of validation results on rectal cancer data in different groups of files. For
each dataset the classifier with the highest overall accuracy was reported. The time-dependent ROC and
Kaplan-Meier analyses on tumor biopsies data were not reported as they were not significant.
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Table 5.27 Summary of validation results of 9-gene signature on rectal cancer data.

57.10

(Sensitivity +
Specificity)/2
(%)
72.30

Overall
accuracy
(%)
78.26

93.80

42.90

68.35

78.26

Lymph node status

75.00

80.00

77.50

76.47

Lymph node status

75.00

60.00

67.50

70.58

55.60

87.50

70.65

73.91

77.80

85.70

81.75

82.60

90.00

28.60

59.30

64.70

80.00

71.40

75.70

76.47

Rectal cancer
data

Classifier

Predicted variable

Sensitivity
(%)

Specificity
(%)

cDNA1 files

AdaboostM1

Lymph node status

87.50

cDNA2 files

AdaboostM1

Lymph node status

Tumor biopsies
1 files
Tumor biopsies
2 files

Decision
stump
J48

cDNA1 files

JRip

cDNA2 files

JRip

Tumor biopsies
1 files
Tumor biopsies
2 files

Random
Committee
Logistic

Chemoradiotherapy
response
Chemoradiotherapy
response
Chemoradiotherapy
response
Chemoradiotherapy
response

5.3 Validation results of the 3-gene signature on rectal cancer data
5.3.1 Predicting lymph node status in tumor biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 2 matching genes (Table 5.28).
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka
software was used for validation and lymph node status (positive/negative) was predicted. Different
classification schemes including KStar, Logistic regression, AD Tree, AdaboostM1, and Threshold
selector were applied to this dataset to find the best scheme. Table 5.29 shows the comparison between
KStar and some of the classifiers used for validation on other datasets. KStar classifier performed better
than the other classifiers. It had a sensitivity of 83.33%, a specificity of 60.00%, and an overall accuracy
of 76.47%. Table 5.30 shows the confusion matrix for KStar classifier. The difference in overall accuracy
between KStar and other classifiers was not statistically significant due to the small sample size.

113

Table 5.28 Matching genes in Ried et al rectal cancer data.
GENE NAME
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

ID
H200012309
H200006643

Table 5.29 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 3-gene signature. The improved overall accuracy of the prediction with the KStar
classifier compared with other methods was assessed by significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

KStar
Logistic regression
AD Tree
AdaboostM1
Threshold selector

83.33
83.30
66.70
58.30
41.70

60.00
40.00
60.00
60.00
80.00

(Sensitivity
+Specificity)/2
(%)
71.66
61.65
63.35
59.15
60.85

Overall
Accuracy
(%)
76.47
70.58
64.70
58.82
52.94

P-value

<0.35
<0.23
<0.14
<0.08

Table 5.30 Confusion matrix obtained from the KStar classifier for predicting lymph node status
using the 3-gene signature.
Actual/Predicted
a (node positive)
b (node negative)

a (node positive)
10
2

b (node negative)
2
3

5.3.2 Predicting chemoradiotherapy response in tumor biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 2 matching genes (Table 5.31).
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different
classification schemes including Decision stump, Multiboost AB, AdaboostM1, Logistic regression, and
AD Tree were applied to this dataset to find the best scheme. Table 5.32 shows the comparison between
Decision stump and some of the classifiers used for validation on other datasets. Decision stump classifier
performed better than the other classifiers. It had a sensitivity of 90.00%, a specificity of 57.10%, and an
overall accuracy of 76.47%. Table 5.33 shows the confusion matrix for Decision stump classifier. The
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difference in overall accuracy between Decision stump and AD Tree (p < 0.04) was statistically
significant.
Table 5.31 Matching genes in Ried et al rectal cancer data.
GENE NAME
E2F2-E2F transcription factor 2 (E2F2)
SLC25A5-solute carrier family 25

ID
H200012309
H200006643

Table 5.32 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 3-gene signature. The improved overall accuracy of the
prediction with the Decision stump classifier compared with other methods was assessed by
significance testing (N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

Decision stump
Multiboost AB
AdaboostM1
Logisitc regression
AD Tree

90.00
90.00
70.00
70.00
50.00

57.10
28.60
42.90
28.60
42.90

(Sensitivity+
Specificity)/2
(%)
73.55
59.30
56.45
49.30
46.45

Overall
Accuracy
(%)
76.47
64.70
58.82
52.94
47.05

P-value

<0.23
<0.14
<0.08
<0.04

Table 5.33 Confusion matrix obtained from the Decision stump classifier for predicting response
using the 3-gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
9
3

b (no response)
1
4

5.3.3 Summary of validation results of 3-gene signature on rectal cancer data
Table 5.34 shows the details of validation results of 3-gene signature on rectal cancer data in different
groups of files. For each dataset the classifier with the highest overall accuracy was reported. The
validation results on cDNA data files, time-dependent ROC and Kaplan-Meier analyses were not reported
as they were not significant.
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Table 5.34 Summary of validation results of 3-gene signature on rectal cancer data.
Rectal cancer
data

Classifier

Predicted variable

Sensitivity
(%)

Specificity
(%)

(Sensitivity +
Specificity)/2
(%)

Overall
accuracy (%)

Tumor biopsies
2 files

KStar

Lymph node status

83.33

60.00

71.66

76.47

Tumor biopsies
2 files

Decision
stump

Chemoradiotherapy
response

90.00

57.10

73.55

76.47

5.4 Validation results of the 5-gene signature on rectal cancer data
5.4.1 Predicting lymph node status in tumor biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 2 matching gene (Table 5.35).
The data used for validation consisted of the expression of these 2 genes in the 17 patient samples. Weka
software was used for validation and lymph node status (positive/negative) was predicted. Different
classification schemes including Multiboost AB, Logitboost, Random Tree, Multilayer perceptron, and
LWL were applied to this dataset to find the best scheme. Table 5.36 shows the comparison between
Multiboost AB and some of the classifiers used for validation on other datasets. Multiboost AB classifier
performed better than the other classifiers. It had a sensitivity of 83.30%, a specificity of 40.00%, and an
overall accuracy of 70.58%. Table 5.37 shows the confusion matrix for Multiboost AB classifier. The
difference in overall accuracy between Multiboost AB and other classifiers was not statistically
significant due to the small sample size.
Table 5.35 Matching genes in Ried et al rectal cancer data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187
SLC25A5-solute carrier family 25

ID
H200013992
H200015602
H200006643
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Table 5.36 Comparison of accuracies obtained from different classifiers for predicting lymph node
status using the 5-gene signature. The improved overall accuracy of the prediction with the
Multiboost AB classifier compared with other methods was assessed by significance testing (N =
17).
Classifier

Sensitivity
(%)

Specificity
(%)

Multiboost AB
Adaboost M1
Random Tree
Random committee
LWL

83.30
83.30
58.30
75.00
75.00

40.00
20.00
20.00
20.00
20.00

(Sensitivity+
Specificity)/2
(%)
61.65
51.65
39.15
47.50
47.50

Overall
Accuracy
(%)
70.58
64.70
47.05
58.82
58.82

P-value

<0.36
<0.09
<0.24
<0.24

Table 5.37 Confusion matrix obtained from the Multiboost AB classifier for predicting lymph node
status using the 5-gene signature.
Actual/Predicted
a (node positive)
b (node negative)

a (node positive)
10
3

b (node negative)
2
2

5.4.2 Predicting chemoradiotherapy response in tumor biopsies 2 files
The tumor biopsies 2 data files from Ried et al (PMID 16397240) consisted of 17 patient samples. The
search for matching genes was done using the gene symbols. There were 3 matching genes (Table 5.38).
The data used for validation consisted of the expression of these 3 genes in the 17 patient samples. Weka
software was used for validation and chemoradiotherapy response (yes/no) was predicted. Different
classification schemes including J48, AD Tree, IB1, Logistic regression, and AdaboostM1 were applied to
this dataset to find the best scheme. Table 5.39 shows the comparison between J48 and some of the
classifiers used for validation on other datasets. J48 classifier performed better than the other classifiers.
It had a sensitivity of 90.00%, a specificity of 57.10%, and an overall accuracy of 76.47%. Table 5.40
shows the confusion matrix for J48 classifier. The difference in overall accuracy between J48 and
Logistic regression (p < 0.04) was statistically significant.
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Table 5.38 Matching genes in Ried et al rectal cancer data.
GENE NAME
TPD52L2-tumor protein D52-like2
ZNF187-zinc finger protein 187
SLC25A5-solute carrier family 25

ID
H200013992
H200015602
H200006643

Table 5.39 Comparison of accuracies obtained from different classifiers for predicting
chemoradiotherapy response using the 5-gene signature. The improved overall accuracy of the
prediction with the J48 classifier compared with other methods was assessed by significance testing
(N = 17).
Classifier

Sensitivity
(%)

Specificity
(%)

J48
AD Tree
IB1
Logistic regression
AdaboostM1

90.00
80.00
50.00
60.00
70.00

57.10
42.90
57.10
28.60
42.90

(Sensitivity+
Specificity)/2
(%)
73.55
61.45
53.55
44.30
56.45

Overall
Accuracy
(%)
76.47
64.70
52.94
47.05
58.82

P-value

<0.23
<0.08
<0.04
<0.14

Table 5.40 Confusion matrix obtained from the J48 classifier for predicting response using the 5gene signature.
Actual/Predicted
a (response)
b (no response)

a (response)
9
3

b (no response)
1
4

5.4.3 Kaplan-Meier analyses on Ried et al rectal cancer data (n=23) using the 5-gene
signature
The cDNA 2 files in rectal cancer data were checked for matching genes with the 5-gene signature. There
were 3 matching genes. The Cox model based on the expression of these 3 genes was used to get
recurrence risk scores for the 23 patients. The choices for choosing a cut-off value for patient
stratification are the peak value from histogram, mean risk score or median risk score. In this analysis, the
median risk score was chosen as cut-off as it resulted in best patient stratification. Cut-off values of 0.17
and -1.16 were chosen for relapse-free survival and overall survival, respectively. The pamr package in R
was used to plot the Kaplan-Meier curves. The low-risk and high-risk groups, had distinct relapse-free
survival (p = 0.043, n=23, log-rank tests), and distinct overall survival (p = 0.036, n=23, log-rank tests),
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respectively for the data in cDNA2 files. Table 5.41 shows the different parameters obtained from the
Cox model using the 9-gene signature for disease-free survival and overall survival in cDNA 2 data files.
Table 5.41 Different parameters obtained from Cox model using the 5-gene signature for relapsefree survival and overall survival.

Gene
Symbol

Disease-free survival
exp
se
coef
(coef)
(coef)

Overall survival
exp
se
z(coef) (coef) score

pvalue

z-score

pvalue

coef

0.86

1.633

5.117

1.96

0.834

0.40

-0.604

0.547

1.52

-0.398

0.69

ZNF187

-0.2148

0.807

1.237

-0.1737

SLC25A5

-0.0006

0.999

0.825

-0.0007

1.00

Figure 5.5 Kaplan-Meier plots on rectal cancer data (n=23) for disease-free survival and overall
survival using the 5-gene signature in cDNA 2 data files.

5.4.4 Summary of validation results of 5-gene signature on rectal cancer data
Table 5.42 shows the details of validation results of 5-gene signature on rectal cancer data in different
groups of files. For each dataset the classifier with the highest overall accuracy was reported. The timedependent ROC, Kaplan-Meier analyses and validation results on cDNA data files were not reported as
they were not significant.
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Table 5.42 Summary of validation results of 5-gene signature on rectal cancer data.
Rectal
cancer data
Tumor
biopsies 2
files
Tumor
biopsies 2
files

Classifier

Predicted variable

Sensitivity
(%)

Specificity
(%)

(Sensitivity +
Specificity)/2
(%)

Overall
accuracy
(%)

MultiboostAB

Lymph node status

83.30

40.00

61.65

70.58

J48

Chemoradiotherapy
response

90.00

57.10

73.55

76.47

5.5 Conclusion
The 9-gene lymph node status signature on the whole had optimal prediction accuracy on the rectal cancer
data set. The 9-gene signature might be used for predicting lymph node status and chemoradiotherapy
response in rectal cancer data and to stratify patients into low-risk and high-risk groups. The 3-gene
signature can be used to predict lymph node status and chemoradiotherapy response of the patients in
tumor biopsies 2 data. The 5-gene signature can be used to stratify patients into low-risk and high-risk
groups, predict lymph node status and chemoradiotherapy response in tumor biopsies 2 data.
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Chapter 6
6.1 Conclusions
The advents of high throughput technologies, such as DNA microarrays are revolutionalizing the field of
medicine. DNA microarrays are a powerful means of monitoring thousands of gene expression levels at
the same time. Machine learning techniques are playing a pivotal role in analyzing the generated
microarray data. Recent studies have successfully applied the machine learning approaches to predict the
cancer stage, treatment outcome, drug response, and promise treatments tailored to the patients. Presently
there are no gene tests available for clinical usage in colon cancer while there are gene tests like
MammaPrint and Oncotype DX for breast cancer prognosis. Our study was focused in the direction of
identifying important biomarkers to predict colon cancer stage and recurrence, building prognostic
models, and stratifying patients into low-risk and high-risk groups based on cDNA microarray data.
In an effort to overcome the limitations of the traditional staging systems, in the first part of our
study a 9-gene lymph node status signature was identified by feature selection using random forests and
then discarding genes without differential expression. A prognostic patient stratification scheme was
developed based on this 9-gene signature using the Cox model. In the second part of the study, we
focused on identifying biomarkers predicting recurrence. This was achieved by a combinatorial scheme
employing feature selection using random forests in the first step and then using InfoGain feature
selection method in the next step. Two recurrence gene signatures were identified and patient
stratification schemes were developed based on these signatures to identify subgroups of patients, at low
and high-risks of recurrence. Recurrence prediction models were built using classifiers in Weka software
based on these gene signatures. The gene signatures identified in this study could be used for classifying
new colon cancer patients into different stages of the disease and different prognostic risk groups.
The analysis of microarray gene expression data through machine learning methods currently
faces two major problems. Firstly the high dimensionality of the feature space and secondly the fact that
gene expression data are very noisy (26). Most of the machine learning algorithms have been developed
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for applications in domains, such as business, retail, and marketing. A typical data mining banking
application, has thousands or millions of records, and at most a few hundred fields. In contrast, a
microarray gene expression data may only have a few hundred records and thousands of fields. Also,
majority of the techniques used in standard data mining applications are very sensitive to noise (1). We
could solve the problem of high dimensionality to some extent by preprocessing the data and employing a
combinatorial scheme for feature selection. In the future, there is a necessity for new machine learning
techniques addressing the high dimensionality and noisy characteristics of microarray gene expression
data. We faced with another problem of availability of colon cancer datasets. The number of colon cancer
datasets publicly available is very less. They are not as widely available as lung cancer and breast cancer
datasets. The colon cancer data used in our study was obtained from our research collaborator Dr.Ried.
The survival information was not available for other colon cancer datasets used for validation and we
could not perform the time-dependent ROC and Kaplan-Meier analyses. Availability of the survival
information and more colon cancer datasets publicly in the future would allow for robust validation of the
identified gene signatures providing us with more understanding of the results.
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